



IBCSG
(formerly, International Breast Cancer Study Group)
Publications

PUBLICATIONS OF THE IBCSG (INTERNATIONAL BREAST CANCER STUDY GROUP)

2026

447. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15000 women in 23 randomised trials. *Lancet* 2026;47(10540):1699-1711. doi: 10.1016/S0140-6736(26)00313-2. Epub 2026 May 2. (IBCSG 24-02) (Journal Impact Factor 88.5).

446. Wang Y, Drubay D, Jonas SF, Dixon-Douglas J, Acs B, Adams S, Andre F, Badve S, Bataillon G, Carter JM, Chia S, Cokenpot V, Colleoni MA, Criscitiello C, Curigliano G, Dackus GMHE, Demaria S, Denkert C, van Deurzen CHM, Dieci MV, Giardiello D, Goetz MP, Gray RJ, Hauptmann M, ter Hoeve ND, Jozwiak K, Koop EA, de Jong VMT, Joensuu H, Jules-Clement G, Kammler R, Kellokumpu-Lehtinen P-L, Kim S-B, Kok M, Lacroix-Triki M, Lambertini M, Lee HJ, Lemonnier J, Leon-Ferre R, Leung S, Linderhol B, Loibl S, Martens JWM, Nielsen TO, Pharoah P, Penault-Llorca F, Piccart M, Pustzai L, Riaz N, Vincent-Salomon A, Shimoi T, Sotiriou C, Suman VJ, Timmermans AM, van Diest PJ, Voogd AC, Viale G, Wolff AC, Yazaki S, Yoshida M, Salgado R, Linn SC, Schmidt MK, Loi S, Michiels S, A report on behalf of the International Immuno-Oncology Biomarker Working Group. Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative-breast cancer survival. *Ann Oncol* 2026. doi: 10.1016/j.annonc.2026.04.011. Epub 2026 Apr 21. (IBCSG Trial 22-00) (Journal Impact Factor 65.4).

445. O'Regan RM, Ren Y, Zhang Y, Fleming GF, Francis PA, Pagani O, Walley BA, Kammler R, Dell'Orto P, Viale G, Loi S, Colleoni M, Treuner K, Regan MM. Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by Breast Cancer Index. *The Breast* 2026;86:104714. doi: 10.1016/j.breast.2026.104714. Epub 2026 Jan 29. (IBCSG 24-02 and IBCSG 25-02) (Journal Impact Factor 7.9).

2025

444. Mayer EL, Hlauschek D, Gnant M, O'Brien PJ, Bellet-Ezquerria M, Goetz MP, Ruiz-Borrego M, Chan A, Clifton K, Egle D, Lake D, Cabrera P, Mamounas T, Pristaux-Telsnigg G, Dayao Z, Gill Gil M, Cameron D, Traina T, Morris PG, Sabanathan D, Rinnerthaler G, Meisel J, Prat A, Wolff AC, Tseng LM, Issacs C, Singer CF, Rubovszky G, Foukakis T, Jassem J, Winder EP, Vetter M, Federmann J, Metzger O, Schurmans C, Gauthier E, Lu DR, Fesl C, Dueck A, DeMichele A. Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109BIG-14-13). *Ann Oncol* 2026;37(2):271-277. doi: 10.1016/j.annonc.2025.10.003. Epub 2025 Oct 17. (IBCSG 52-15) (Journal Impact Factor 65.4).

443. O'Regan RM, Ren Y, Zhang Y, Siuliukina N, Schnabel CA, Kammler R, Viale G, Dell'Orto P, Munzone E, Lang I, Tondini C, Gomez HL, Chini C, Nicoletti SVL, Puglisi F, Zaman K, Goetz MP, Stearns V, Martino S, Salim M, Loibl S, Geyer CE Jr, Bonnefoi HR, Ciruelos EM, Loi S, Colleoni M, Fleming GF, Francis PA, Walley BA, Pagani O, Treuner K, Regan MM. Assessment of adjuvant endocrine therapy with ovarian function suppression by Breast Cancer Index. *JAMA Netw Open* 2025;8(11):e2540931. doi: 10.1001/jamanetworkopen.2025.40931. Epub 2025 Nov 3. (IBCSG 24-02 and IBCSG 25-02) (Journal Impact Factor 9.7).

442. Malorni L, Tyekucheva S, Gombos A, Hasler-Stub U, Zamgani C, Chakiba-Brugere, Colleoni M, Mueller A, Minisini AM, Taylor D, Salmon JP, Gallerani E, Cariello A, Fontana A, Roschitzki-Voser H, Kammler R, Ruepp B, Loi S, Viale G, Regan MM, Brain E, Biganzoli L; International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation) and the TOUCH Trial (IBCSG 55-17) Investigators. Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17). *Ann Oncol* 2025;37(2):194-205. doi: 10.1016/j.annonc.2025.10.016. Epub 2025 October 16. (IBCSG 55-17) (Journal Impact Factor 65.4).

441. Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP; Panelists of the St Gallen International Breast Cancer Consensus 2025. Tailoring treatment to cancer risk and patient preference: The 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer. *Ann Oncol* 2025;36(12):1433-1446. doi: 10.1016/j.annonc.2025.09.007. Epub 2025 October 8. (Journal Impact Factor 65.4).

440. Ribi K, Cole BF, Fleming GF, Walley BA, Francis PA, Abdi E, Burstein HJ, Cheng KL, Chia SKL, Dakhil SR, Davidson NE, Della-Fiorentina SA, Frith AE, Levine E, Lupichuk S, Pritchard K, Salim M, Stearns V, Stewart J, Valero V, van der Westhuizen A, Pagani O, Loi S, Colleoni M, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J. Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT. *Cancer* 2025;131(19):e70094. doi: 10.1002/cncr.70094. Epub 2025 September 23. (IBCSG 24-02 and 25-02) (Journal Impact Factor 5.1).

439. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155,746 women in 151 trials. *Lancet* 2024;404(10461):1407-1418. doi: 10.1016/S0140-6736(24)01745-8. Epub 2024 Oct 12. (IBCSG VI, VIII, IX, 10-93, 11-93, 12a-93, 13-93, 14a-93, 15-95, 24-02, 25-02, 30-04, and BIG 1-98) (Journal Impact Factor 88.5).
438. Demeestere I, Niman SM, Partridge AH, Diego DS, Kammler R, Ruggeri M, Colleoni M, Shimizu C, Saura C, Gelmon KA, Saetersdal AB, Kroep JR, Mailliez A, Amant F, Ruiz-Borrego M, Lee JE, Kataoka A, Walshe JM, Takei J, Borstnar S, Borges VF, Saunders C, Susnjar S, Bjelic-Radisic V, Cardoso F, Meisel JL, Kawwass JF, Spanic T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr, Peccatori FA, for the International Breast Cancer Study Group and the POSITIVE Trial Collaborators. Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in the POSITIVE Trial. *Breast* 2025;83:104547. doi: 10.1016/j.breast.2025.104547. Epub 2025 July 26. (IBCSG 48-14) (Journal Impact Factor 7.9).
437. Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Gelmon K, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr, for the International Breast Cancer Study Group and the POSITIVE Trial Collaborators. Breastfeeding after hormone receptor-positive breast cancer: Results from the Positive Trial. *J Clin Oncol* 2025;43(24):2712-2719. doi: 10.1200/JCO-24-02697. Epub 2025 July 9. (IBCSG 48-14) (Journal Impact Factor 42.1).
436. Joaquin Garcia A, Semba T, Rediti M, McGrail DJ, Xie X, Wang X, Rampa DR, Venet D, Buisseret L, Majjaj S, Kammler R, Colleoni M, Loi S, Viale G, Regan MM, Rothe F, Sotiriou C, Ueno NT. Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG Trial 22-00. *iScience* 2025;28(8):112964. doi: 10.1016/j.isci.2025.112964. Epub 2025 June 20. (IBCSG 22-00) (Journal Impact Factor 4.6).
435. Biganzoli G, Richard F, Isnaldi E, Marano G, Boracchi P, Maetens M, Floris G, Neven P, Jerusalem G, Munzone E, Hitre E, Gombos A, Thompson A, Aebi S, Kammler R, Dell'Orto P, Viale G, Regan MM, Colleoni M, Biganzoli E, Desmedt C. Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial. *Eur J Cancer* 2025;222:115438. doi: 10.1016/j.ejca.2025.115438. Epub 2025 Apr 17. (IBCSG 35-07) (Journal Impact Factor 7.6).
434. Zdenkowski N, Kuper-Hommel MJJ, Niman SM, Francis PA, Baron-Hay S, Fox W, Menzies AM, Angus R, Punie K, Zardawi, Regan MM, Loi S. Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): A non-comparative, open-label, randomised, phase 2 trial. *Lancet Oncol* 2025;26(3):367-377. doi:10.1016/S1470-2045(24)00757-5. Epub 2025 Mar. (IBCSG 61-20) (Journal Impact Factor 41.6).
433. Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, Chui SY, Dieterich M, Perretti T, Shearer-Kang E, Molinero L, Steger GG, Jassem J, Chin Lee S, Higgins M, Zarba J, Schmidt M, Gomez H, Guerrero Zotano A, Moscetti L, Chiu J, Munzone E, Efrat Ben-Baruch N, Bajetta E, Ohno S, Im S-A, Werutsky G, Nili Gal-Yam E, Gonzalez Farre X, Tseng L-M, Jacot W, Gluz O, Shao Z, Shparyk Y, Zimina A, Winer E, Cameron DA, Viale G, Saji S, Gelber R, Piccart M. Adjuvant atezolizumab for early triple-negative breast cancer: The ALEXANDRA/Impassion030 randomized clinical trial. *JAMA* 2025;333(13):1150-1160. doi: 10.1001/jama.2024.26886. Epub 2025 Jan 30. (IBCSG 56-17) (Journal Impact Factor 63.5).
432. Luen SJ, Brown LC, van Geelen CT, Savas P, Kammler R, Dell'Orto P, Biasi O, Coates AS, Gelber RD, Thuerlimann B, Colleoni M, Fleming GF, Francis PA, Regan MM, Viale G, Loi S. Genomic characterization and prognostic significance of HER2-low, hormone receptor-positive, early breast cancers from the BIG 1-98 and SOFT clinical trials. *JCO Precis Oncol* 2025;9e2400599. doi: 10.1200/PO-24-00599. Epub 2025 Jan 24. (BIG 1-98 and IBCSG 24-02) (Journal Impact Factor 5.3).

2024

431. de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A. Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]. *ESMO Open* 2024;9(11):103938. doi: 10.1016/j.esmoop.2024.103938. Epub 2024 Oct 17. (IBCSG 36-07) (Journal Impact Factor 7.1).

430. Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive breast cancer in the APHINITY trial: Third interim overall survival analysis with efficacy update. *J Clin Oncol* 2024;42(31):3643-3651. doi: 10.1200/JCO.23.02505. Epub 2024 Sep 11. (IBCSG 39-11) (Journal Impact Factor 42.1).
429. O'Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell'Orto P, Láng I, Bellet M, Bonnefoi HR, Tondini C, Villa F, Bernardo A, Ciruelos EM, Neven P, Karlsson P, Müller B, Jochum W, Zaman K, Martino S, Geyer CE Jr, Jerzak KJ, Davidson NE, Coleman RE, Ingle JN, van Mackelenbergh MT, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM. Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT Trial. *JAMA Oncol* 2024;10(10):1379-1389. doi: 10.1001/jamaoncol.2024.3044. Epub 2024 Aug 15. (IBCSG 24-02) (Journal Impact Factor 22.3).
428. Pagan E, Ruggeri M, Bianco N, Bucci EO, Graffeo R, Borner M, Giordano M, Gianni L, Rabaglio M, Freschi A, Cretella E, Seles E, Farolfi A, Simoncini E, Ciccarese M, Rauch D, Favaretto A, Honecker F, Berardi R, Franzetti-Pellanda A, Gelber S, Partridge AH, Goldhirsch A, Bagnardi V, Pagani O, Ribbi K. Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer. *The Breast* 2024;77:103765. doi: 10.1016/j.breast.2024.103765. Epub 2024 July 4. (IBCSG 43-09) (Journal Impact Factor 5.7).
427. Azim HA Jr, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjak S, Cardoso F, Klar NJ, Spanic T, Ruddy K, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Peccatori FA. Fertility preservation and assisted reproduction in breast cancer patients interrupting adjuvant endocrine therapy to attempt pregnancy. *J Clin Oncol* 2024;42(23):2822-2832. doi: 10.1200/JCO.23.02292. Epub 2024 May 29. (IBCSG 48-14) (Journal Impact Factor 42.1).
426. Peters S, Loi S, André F, Chandarlapaty S, Filip E, Finn SP, Jänne PA, Kerr KM, Munzone E, Passaro A, Pérol M, Smit EF, Swanton C, Viale G, Stahel RA. Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation. *Ann Oncol* 2024;35(7):607-629. doi: 10.1016/j.annonc.2024.04.002. Epub 2024 Apr 20. (Journal Impact Factor 56.7).
425. Ganz PA, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, Delalogue S, Brain E, Toi M, Yamauchi H, de Duenas E-M, Armstrong A, Im S-A, Song C-G, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Seok Lee L, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer Jr CE, Tutt ANJ. Patient-reported outcomes in OlympiA: A phase III, randomized, placebo-controlled trial of adjuvant olaparib in g BRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer. *J Clin Oncol* 2024;42(11):1288-1300. doi: 10.1200/JCO.23.01214. Epub 2024 Feb 1. (IBCSG 50-14) (Journal Impact Factor 42.1).
424. Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thuerlimann B, Pruneri G, Gray K, Lang I, Regan MR, Loi S, Colleoni M, Viale G, Kandalaf L, Coukos G, Curigliano G. Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00. *Eur J Cancer* 2024;200:113535. doi: 10.1016/j.ejca.2024.113535. Epub 2024 Jan 24. (IBCSG 22-00) (Journal Impact Factor 7.6).

2023

423. Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Thuerlimann B; St Gallen Consensus Conference Panelists 2023. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. *Ann Oncol*. 2023;34(11):970-986. doi: 10.1016/j.annonc.2023.08.017. Epub 2023 Sep 6. (Journal Impact Factor 51.769).
422. Joaquin Garcia A, Rediti M, Venet D, Majjaj S, Kammler R, Munzone E, Gianni L, Thuerlimann B, Láng I, Colleoni M, Loi S, Viale G, Regan MM, Buisseret L, Rothé F, Sotiriou C. Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00. *Clin Cancer Res* 2023;29(23):4908-4919. doi: 10.1158/1078-0432.CCR-23-1267. Epub 2023 Sept 21. (IBCSG 22-00) (Journal Impact Factor 11.500).

421. Munzone E, Regan MM, Cinieri S, Montagna E, Orlando L, Shi R, Campadelli E, Gianni L, Palleschi M, Petrelli F, Bengala C, Generali D, Collovà E, Puglisi F, Cretella E, Zamagni C, Chini C, Ruepp B, Loi S, Colleoni M; International Breast Cancer Study Group (IBCSG). Efficacy of metronomic oral vinorelbine, cyclophosphamide, capecitabine vs weekly paclitaxel in patients with estrogen receptor-positive, ERBB-negative metastatic breast cancer: Final results from the phase 2 METEORA-II randomized clinical trial. *JAMA Oncol* 2023;9(9):1267-1272. doi: 10.1001/jamaoncol.2023.2150. Epub 2023 Jul 13. (IBCSG 54-16) (Journal Impact Factor 33.012).

420. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribí K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, for the International Breast Cancer Study Group and the POSITIVE Trial Consortium, Steering Committee and Investigators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. *N Engl J Med* 2023;388(18):1645-1656. doi: 10.1056/NEJMoa2212856. (IBCSG 48-14) (Journal Impact Factor 176.079).

419. Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperis A, Brown LC, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller B, Joshum W, Bonnefoi H, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Ingle JN, Coleman R, Solbach C, Thuerlimann B, Colleoni M, Coates AS, Goldhirsch A, Fleming GF, Francis PA, Speed TP, Regan MM, Loi S. Genomic characterisation of hormone receptor-positive breast cancer arising in young women. *Ann Oncol* 2023;34(4):397-409. doi: 10.1016/j.annonc.2023.01.009. Epub 2023 Jan 25. (IBCSG 24-02) (Journal Impact Factor 51.769).

2022

418. Nuciforo P, Townend J, Piccart MJ, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Moreno Aspitia A, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. *Eur J Cancer* 2023;181:92-101. doi: 10.1016/j.ejca.2022.12.020. Epub 2022 Dec 27. (IBCSG 37-07) (Journal Impact Factor 10.002).

417. Geyer CE Jr, Garber J, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui KY, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmana J, Bergh J, Bliss J, Delalogue S, Domchek SM, Eisen A, Elsayf F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im S-A, Jager A, Johannsson OP, Lakhani SR, Janni W, Linderholm B, Liu T-W, Loman N, Korde L, Loibl S, Lucas PC, Marme F, Martinez de Duenas E, McConnell R, Phillips K-A, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Spanic T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt AN; Olympia Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant Olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. *Ann Oncol* 2022;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. (IBCSG 50-14) (Journal Impact Factor 51.769).

416. Pagani* O, Walley* BA, Francis GF, Colleoni M, Láng I, Gomez HI, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winder EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan** MM, Francis** PA, for the SOFT and TEXT Investigators and the International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. *Co-lead authors. **Co-last authors. *J Clin Oncol* 2023;41(7):1376-1382. doi: 10.1200/JCO.22.01064. Epub 2022 Dec 15. (IBCSG 24-02 and 25-02) (Journal Impact Factor 50.717).

415. Francis* PA, Fleming* GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE Jr, Walley BA, Ingle JN, Coleman RE, Müller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM, for the SOFT Investigators and the International Breast Cancer Study Group. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. *Co-lead authors. *J Clin Oncol* 2023;41(7):1370-1375. doi: 10.1200/JCO.22.01065. Epub 2022 Dec 9. (IBCSG 24-02) (Journal Impact Factor 50.717).

414. Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu T TT, Muanza TM, Neal A, Olivetto IA, BIG 3-07/TROG 07.01 trial investigators. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. *Lancet* 2022;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6. Epub 2022 Aug 6. (IBCSG 38-10) (Journal Impact Factor 202.731).

413. Ribi K, Pagan E, Sala I, Ruggeri M, Bianco N, Oreste Bucci E, Graffeo R, Borner M, Giordano M, Gianni L, Rabaglio M, Freschi A, Cretella E, Seles E, Farolfi A, Simoncini E, Ciccarese M, Rauch D, Favaretto A, Glaus A, Berardi R, Franzetti-Pellanda A, Bagnardi V, Gelber S, Partridge AH, Goldhirsch A, Pagani O. Employment trajectories of young women with breast cancer: An ongoing prospective cohort study in Italy and Switzerland. *J Cancer Surviv* 2023;17(6):1847-1858. doi: 10.1007/s11764-002-01222-y. Epub 2022 June 10. (IBCSG 43-09) (Journal Impact Factor 4.062).
412. Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: The MA.32 randomized clinical trial. *JAMA* 2022;327(20):1963-1973. doi: 10.1001/jama.2022.6147. Epub 2022 May 24. (IBCSG 40-11) (Journal Impact Factor 157.3).
411. Pérez-Fidalgo JA, Criscitiello C, Carrasco E, Regan MM, Di Leo A, Ribi K, Adam V, Bedard PL. A phase 3 trial of alpelisib+trastuzumab+/-fulvestrant vs trastuzumab+chemotherapy in HER2+ PIK3CA-mutated breast cancer. *Future Oncol* 2022;18(19):2339-2349. doi: 10.2217/fon-2022-0045. Epub 2022 Apr 25. (Special article / review) (IBCSG 62-20) (Journal Impact Factor 3.674).
410. Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, DeSwert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart* M, Regan* MM. Serum thymidine kinase activity in patients with hormone receptor positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. *Co-last authors. *Eur J Cancer* 2022;164:39-51. doi: 10.1016/j.ejca.2021.12.030. Epub 2022 Feb 13. (IBCSG 53-14) (Journal Impact Factor 9.162).
409. Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Pan H, Peto R, Dodwell D, McGale P, Taylor C, Bergh J, Swain S, Francis PA, Gnant M, Perrone F, Regan MM, for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: Patient level meta-analysis of 7,030 women in four randomised trials. *Lancet Oncol* 2022;23(3):382-392. doi: 10.org/10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3. (IBCSG 24-02 and 25-02) (Journal Impact Factor 41.316).
408. Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Vittoria Dieci M, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, Michiels S. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (Brief communication). *npj Breast Cancer* 2022;8(1):3. doi: 10.1038/s41523-021-00362-1. Epub 2022 Jan 11. (IBCSG 22-00). (Journal Impact Factor 7.519).

2021

407. Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL, on behalf of the PALLAS groups and investigators. Adjuvant palbociclib for early breast cancer: The PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). *J Clin Oncol* 2022;40(3):282-293. doi: 10.1200/JCO.21.02554. Epub 2021 Dec 7. (IBCSG 52-15) (Journal Impact Factor 44.544).
406. Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, Zoppoli G, Razis E, Johannsson OT, Colleoni M, Tutt AN, Audeh W, Ignatiadis M, Mailliez A, Trédan O, Musolino A, Vuylsteke P, Juan-Fita MJ, Macpherson IRJ, Kaufman B, Manso L, Goldstein LJ, Ellard SL, Láng I, Jen KY, Adam V, Litière S, Erban J, Cameron DA; BRAVO Steering Committee and the BRAVO Investigators. Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. *Clin Cancer Res* 2021;27(20):5482-5491. doi: 10.1158/1078-0432.CCR-21-0310. Epub 2021 Jul 22. (IBCSG 47-14). (Journal Impact Factor 12.531).

405. Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers E, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisdottir A, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE, Johannsson OT, Bedard PL, Loi S, Knox S, Cameron DA, Harbeck N, Montoya ML, Brandão M, Vingiani A, Caballero C, Hilbers FS, Yates LR, Benelli M, Venet D, Piccart MJ. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. *Cancer Discov* 2021;11(11):2796-2811. doi: 10.1158/2159-8290.CD-20-1647. Epub 2021 Oct 11. (IBCSG 51-14) (Journal Impact Factor 39.397).
404. Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Seiler S, Maddox C, Ruhstaller T, Muenst S, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Kurzeder C, Újhelyi M, Vrieling C, Satler R, Meyer I, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maraz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Dubsy P, Exner R, Fansa H, Hager C, Reisenberger K, Singer CF, Reitsamer R, Reinisch M, Winkler J, Thanh Lam G, Fehr MK, Naydina T, Kohilk M, Clerc K, Ostapenko V, Fitzal F, Nussbaumer R, Maggi N, Schulz A, Markellou P, Lelièvre L, Egle D, Heil J, Knauer M. Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Breast* 2021;60:98-110. doi: 10.1016/j.breast.2021.09.004. Epub 2021 Sept 8. (IBCSG 57-18) (Journal Impact Factor 4.380).
403. Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, Neven P, Hitre E, Graas MP, Simoncini E, Abdi E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Gombos A, Ruhstaller T, Burstein HJ, Rabaglio M, Ruepp B, Ribí K, Viale G, Gelber RD, Coates AS, Loi S, Goldhirsch A, Regan* MM, Colleoni* M on behalf of the SOLE Investigators. Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. *Co-last authors. *Ann Oncol* 2021;32(10):1256-1266. doi: 10.1016/j.annonc.2021.07.017. Epub 2021 Aug 10. (IBCSG 35-07) (Journal Impact Factor 32.976).
402. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HCF, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O. Who are the women who enrolled in the POSITIVE Trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy? *Breast* 2021;59:327-338. doi: 10.1016/j.breast.2021.07.021. Epub 2021 Aug 3. (IBCSG 48-14) (Journal Impact Factor 4.380).
401. Goodwin PJ, Dowling RJO, Ennis M, Chen BE, Parulekar WR, Shepherd LE, Gelmon KA, Whelan TJ, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Rastogi P, Rabaglio-Poretti M, Lemieux J, Thompson AM, Rea DW, Stambolic V. Cancer antigen 15-3/mucin 1 levels in CCTG MA.32: A breast cancer randomized trial of metformin vs placebo. *JNCI Cancer Spectr* 2021;5(5):pkab066. doi: 10.1093/jncics/pkab066. Epub 2021 July 28. (IBCSG 40-11).
400. Burstein HJ, Curigliano G, Thuerlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M, Panelists of the St. Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. *Ann Oncol* 2021;32(10):1216-1235. doi: 10.1016/j.annonc.2021.06.023. Epub 2021 July 6. (Special article) (Journal Impact Factor 32.976).
399. Goodwin PJ, Dowling RJO, Ennis M, Chen BE, Parulekar WR, Shepherd LE, Burnell MJ, Vander Meer R, Molckovsky A, Gurjal A, Gelmon KA, Ligibel JA, Hershman DL, Mayer IA, Whelan TJ, Hobday TJ, Rastogi P, Rabaglio M, Lemieux J, Thompson AM, Rea DW, Stambolic V. Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. *npj Breast cancer* 2021;7(1):74. doi: 10.1038/s41523-021-00275-z. Epub 2021 June 8. (IBCSG 40-11) (Journal Impact Factor 6.000).
398. Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, Hershman DL, Whelan T, Stambolic V, Mayer I, Hobday T, Lemieux J, Thompson A, Rastogi P, Gelmon K, Rea D, Rabaglio M, Ellard S, Mates M, Bedard P, Pitre L, Vandenberg T, Dowling RJO, Parulekar W, Goodwin PJ. The effect of metformin vs placebo on sex hormones in Canadian Cancer Trials Group MA.32. *J Natl Cancer Inst* 2021;113(2):192-198. doi: 10.1093/jnci/djaa082. (IBCSG 40-11) (Journal Impact Factor 11.577).
397. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmana J, Domcheck SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantzis V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; for the OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated Breast Cancer. *N Engl J Med* 2021;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 June 3. (IBCSG 50-14) (Journal Impact Factor 74.669).

396. Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber RD, Piccart-Gebhart M, for the ALTO Steering Committee and Investigators. Updated results from the International Phase III ALTO Trial (BIG 2-06/Alliance N063D). *Eur J Cancer* 2021;148:287-296. doi: 10.1016/j.ejca.2021.01.053. Epub 2021 March 22. (IBCSG 36-07) (Journal Impact Factor 7.275).

395. Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pieńkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G, Thomssen C; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY Trial: 6 years' follow-up. *J Clin Oncol* 2021;39(13):1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021 Feb 4. (IBCSG 39-11) (Journal Impact Factor 44.544).

394. Mayer EL, Dueck C, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerria M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, Dufrane C, Fumagalli D, Puyana Theall K, Lu DR, Huang Bartlett C, Koehler M, Fesl C, DeMichele A, Gnant M. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): Interim analysis of a multicentre, open-label, randomized, phase 3 study. *Lancet Oncol* 2021;22(2):212-222. doi: 10.1016/S1470-2045(20)30642-2. Epub 2021 Jan 15. (IBCSG 52-15) (Journal Impact Factor 33.752).

2020

393. Gelber RD, Coates AS, Gelber S, Orecchia R, Veronesi P, Di Leo A, Colleoni M, Winer EP, Burstein HJ, Viale G, Senn H-J, Piccart M, Curigliano G. The legacy of Professor Aron Goldhirsch. *Ann Oncol* 2020;31(6):671-673. doi: 10.1016/j.annonc.2020.03.288. Epub 2020 Mar 23. (Journal Impact Factor 18.274).

392. Piccart MJ, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, Naït Kaoudjt R, Schumacher E, Spears PA, Regan MM, Gelber RD, Davidson NE, Norton L, Winer EP; BIG-NABCG Collaboration. Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors. *J Clin Oncol* 2020;38(34):4120-4129. doi: 10.1200/JCO.20.01382. Epub 2020 Oct 14. (Journal Impact Factor 32.956).

391. Leone JP, Cole BF, Regan MM, Thuerlimann B, Coates AS, Rabaglio M, Giobbie-Hurder A, Gelber RD, Ejlertsen B, Harvey VJ, Neven P, Láng I, Bonnefoi H, Wardley A, Goldhirsch A, Di Leo A, Colleoni M, Vaz-Luis I, Lin NU. Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 Clinical Trial. *Cancer* 2021;127(5):700-708. doi: 10.1002/cncr.33318. Epub 2020 Dec 8. (BIG 1-98) (Journal Impact Factor 5.772).

390. Guerini-Rocco E, Gray KP, Fumagalli C, Reforgiato MR, Leone I, Raviele PR, Munzone E, Kammler R, Neven P, Hitre E, Jerusalem G, Simoncini EL, Gombos A, Deleu I, Karlsson P, Aebi S, Chirgwin J, Di Lauro V, Thompson AM, Grass M-P, Barber M, Fontaine C, Loibl S, Gavilá, Kuroi K, Müller B, O'Reilly S, Di Leo A, Goldhirsch A, Viale G, Barberis M, Regan MM, Colleoni M. Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE trial. *Clin Cancer Res* 2021;27(2):504-512. doi: 10.1158/1078-0432.CCR-20-0126. Epub 2020 Oct 20. (IBCSG 35-07) (Journal Impact Factor 10.107).

389. Rabaglio M, Sun Z, Maibach R, Giobbie-Hurder A, Ejlertsen B, Harvey VJ, Neven P, Láng I, Bonnefoi H, Wardley A, Ruepp B, Castiglione M, Coates AS, Gelber RD, Goldhirsch A, Colleoni M, Thuerlimann B, Regan MM. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: A report from the BIG 1-98 trial. *Breast Cancer Res Treat* 2021;185(3):697-707. doi: 10.1007/s10549-020-05981-z. Epub 2020 Nov 7. (BIG 1-98) (Journal Impact Factor 3.831).

388. Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi M, Demanse D, Hackl W, Thuerlimann B, Viale G, Di Leo A, Colleoni M, Regan* MM, Loi* S. Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. *Co-last authors. *Ann Oncol* 2020;31(10):1359-1365. doi: 10.1016/j.annonc.2020.06.024 Epub 2020 July 8. (BIG 1-98) (Journal Impact Factor 18.274).

387. Sun Z, Niman SM, Pagani O, Partridge AH, Azim HA, Peccatori FA, Ruggeri M, Di Leo A, Colleoni M, Gelber RD, Regan MM; POSITIVE Steering Committee and Investigators. Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial. *Breast* 2020;53:1-7. doi: 10.1016/j.breast.2020.05.012. Epub 2020 Apr 9. (IBCSG 48-14) (Journal Impact Factor 3.494).

386. King MT, Link ET, Whelan TJ, Olivotto LA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH, on behalf of BIG 3-07/TROG 07.01 trial investigators. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. *Lancet Oncol* 2020;21(5):685-698. doi: 10.1016/S1470-2045(20)30085-1. Epub 2020 Mar 20. (IBCSG 38-10) (Journal Impact Factor 33.752).

385. Ribí K, Luo W, Walley BA, Burstein HJ, Chirgwin J, Ansari RH, Salim M, van der Westhuizen A, Abdi E, Francis PA, Chia S, Harvey VJ, Giobbie-Hurder A, Fleming GF, Pagani O, Di Leo A, Colleoni M, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. *Breast Cancer Res Treat* 2020;181(2):347-359. doi: 10.1007/s10549-020-05622-5. Epub 2020 Apr 9. (IBCSG 24-02 and 25-02) (Journal Impact Factor 3.471).

384. Fackler MJ, Cho S, Cope L, Gabrielson E, Visvanathan K, Wilsbach K, Meir-Levi D, Lynch CF, Marks J, Geradts J, Regan MM, Viale G, Wolff AC, Sukumar S, Umbricht CB. DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. *NPJ Breast Cancer* 2020;6:3. doi: 10.1038/s41523-020-0145-3 Epub 2020 Jan 31. (IBCSG VIII and IX) (Journal Impact Factor 6.230).

2019

383. Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber RD, Piccart-Gebhart M, Di Cosimo M. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer *Eur J Cancer* 2019;118:169-177. doi: 10.1016/j.ejca.2019.04.038. (IBCSG 37-07) (Journal Impact Factor 6.680).

382. Varga S, Li Q, Jochum W, Perriard U, Rau T, Tille J-C, Hawle H, Klingbiel D, Thuerlimann B, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. *Sci Rep* 2019;9:13534. doi: 10.1038/s41598-019-49638-4. (IBCSG VIII and IX) (Journal Impact Factor 4.011).

381. Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Lang I, Gomez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: Results from TEXT and SOFT. *J Clin Oncol* 2020;38(12):1293-1303. doi: 10.1200/JCO.18.01967. Epub 2019 Oct 16. (IBCSG 24-02 and 25-02) (Journal Impact Factor 26.303).

380. Denkert C, Budczies J, Regan MM, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua MG, Solbach C, Thuerlimann B, Mehta K, Blohmer JU, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner BM, Dietel M, Fasching PA, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. *Breast Cancer Res Treat* 2019;176(3):557-568. doi: 10.1007/s10549-018-05112-9. Epub 2019 May 7. (IBCSG VIII, IX, BIG 1-98) (Journal Impact Factor 3.471).

379. Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TP, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E. Neoadjuvant letrozole plus taselelisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol* 2019;20(9):1226-1238. doi: 10.1016/S1470-2045(19)30334-1. Epub 2019 Aug 8. (IBCSG 46-13) (Journal Impact Factor 36.418).

378. Buechler S, Gray KP, Gökmen-Polar Y, Willis S, Thuerlimann B, Kammler R, Viale G, Leyland-Jones B, Badve* SS, Regan* MM. Independent validation of EarlyR gene signature in BIG 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. *Co-last authors. *JNCI Cancer Spectr* 2019;3(4):pkz051. doi: 10.1093/jncics/pkz051. eCollection 2019 Dec. (BIG 1-98).

377. Ruggeri M, Pagan E, Bagnardi V, Bianco N, Gallerani E, Buser K, Giordano M, Gianni L, Rabaglio M, Freschi A, Cretella E, Clerico M, Farolfi A, Simoncini E, Ciccarese M, Rauch D, Ramello M, Glaus A, Berardi R, Franzetti Pellanda A, Ribí K, Gelber S, Partridge AH, Goldhirsch A, Pagani O. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers. *Breast* 2019;47:85-92. doi: 10.1016/j.breast.2019.07.001. Epub 2019 Jul 10. (IBCSG 43-09) (Journal Impact Factor 3.494).

376. Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber RD. Are we assuming too much with our statistical assumptions? Lessons learned from the ALTO trial. *Ann Oncol* 2019;30(9):1507-1513. doi: 10.1093/annonc/mdz195. Epub 2019 Jun 26. (IBCSG 36-07) (Journal Impact Factor 13.926).
375. Ribí K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J, SOLE Investigators. Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. *Br J Cancer* 2019;120(10):959-967. doi: 10.1038/s41416-019-0435-4. Epub 2019 Apr 10. Correction 2020 Jan 16. doi: 10.1038/s41416-019-0709-x. (IBCSG 35-07) (Journal Impact Factor 5.922).
374. Regan MM, Fleming GF, Walley B, Francis PA, Pagani O. Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: Lights and shadows. *J Clin Oncol* 2019;37(11):862-866. doi: 10.1200/JCO.18.02433. Epub 2019 Feb 27. (Commentary) (IBCSG 24-02 and 25-02) (Journal Impact Factor 26.303).
373. Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thuerlimann B, Colleoni M, Viale G, Brown M, Tamimi RM. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. *Breast Cancer Res* 2019;21(1):30. doi: 10.1186/s13058-019-1118-z. (BIG 1-98) (Journal Impact Factor 6.142).
372. Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. *J Clin Oncol* 2019;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16. (meta-analysis; IBCSG 22-00) (Journal Impact Factor 26.303).
371. Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. *Lancet Oncol* 2019;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11. (IBCSG 45-13) (Journal Impact Factor 36.418).

2018

370. Dellapasqua S, Gray KP, Munzone E, Rubino D, Gianni L, Johansson H, Viale G, Ribí K, Bernhard J, Kammler R, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Colleoni M; International Breast Cancer Study Group. Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: A randomized phase II trial. *J Clin Oncol* 2019;37(3):386-395. doi: 10.1200/JCO.18.00296. Epub 2018 Dec 27. (IBCSG 41-13) (Journal Impact Factor 26.303).
369. Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thuerlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: Long-term follow-up of the BIG 1-98 Trial. *J Clin Oncol* 2019;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26. (BIG 1-98) (Journal Impact Factor 26.303).
368. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. *J Natl Cancer Inst* 2019;111(2):210-213. doi: 10.1093/jnci/djy185. Epub 2018 Oct 27. (IBCSG 34-05) (Journal Impact Factor 12.589).
367. Galimberti V, Cole BF, Viale G, Peronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. *Lancet Oncol* 2018;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2. Epub 2018 Sept 5. (IBCSG 23-01) (Journal Impact Factor 36.418).

366. Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Bouckaert O, Wildiers H, Floris G, van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thuerlimann B, Vergote I, Christodoulou E, van Calster B, Neven P. Prognostic value of progesterone receptor by subtype in patients with estrogen receptor-positive, HER-2 negative breast cancer. *Oncologist* 2019;24(2):165-171. doi: 10.1634/theoncologist.2018-0176. Epub 2018 Aug 31. (BIG 1-98) (Journal Impact Factor 5.306).
365. Procter M, Robertson C. Performance of standard imputation methods for missing quality of life data as covariate in survival analysis based on simulations from the International Breast Cancer Study Group Trials VI and VII*. *Communications in Statistics – Simulation Computation* 2019;48(10):3063-3077. doi: 10.1080/03610918.2018.1473587. Epub 2018 Aug 12. (IBCSG VI, VII) (Journal Impact Factor 0.457).
364. Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi OM, Demanse D, JeBailey L, Dolan S, Hackl W, Thuerlimann B, Viale G, Colleoni M, Regan MM, Loi S. Association of somatic driver alterations with prognosis in postmenopausal, hormone receptor-positive, HER2-negative early breast cancer: A secondary analysis of the BIG 1-98 randomized clinical trial. *JAMA Oncol* 2018;4(10):1335-1343. doi: 10.1001/jamaoncol.2018.1778. Epub 2018 Jun 14. (BIG 1-98) (Journal Impact Factor 16.559).
363. Francis PA*, Pagani O*, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer Jr. CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A**, Regan MM**, the SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. *Co-first authors; **Co-last authors. *N Engl J Med* 2018;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4. (IBCSG 24-02 and 25-02) (Journal Impact Factor 72.406).
362. Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber RD, Campbell I, Nordenskjöld B, Gutiérrez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA. Postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes: Analysis of the Breast International Group 02-98 Trial. *Int J Radiat Oncol Biol Phys* 2018;101(2):316-324. doi: 10.1016/j.ijrobp.2018.01.105. Epub 2018 Feb 6. (IBCSG 20-98) (Journal Impact Factor 5.133).
361. Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thuerlimann B, Colleoni M, Cuzick J. Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy: CTS5. *J Clin Oncol* 2018;36(19):1941-1948. doi: 10.1200/JCO.2017.76.4258. Epub 2018 Apr 20. (BIG 1-98) (Journal Impact Factor 26.303).
360. Munzone E, Gray KP, Fumagalli C, Guerini-Rocco E, Láng I, Ruhstaller T, Gianni L, Kammler R, Viale G, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Barberis M, Colleoni M. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. *Breast Cancer Res Treat* 2018;170(2):351-360. doi: 10.1007/s10549-018-4767-1. Epub 2018 Mar 27. (IBCSG 22-00) (Impact Factor 3.626).
359. Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Paterson AHG, Rimawi MF, Lang I, Baena-Cañada JM, Thuerlimann B, Mamounas EP, Geyer Jr CE, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S, International Breast Cancer Study Group, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Breast International Group. Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR Trial. *J Clin Oncol* 2018;36(11):1073-1079. doi: 10.1200/JCO.2017.76.5719. Epub 2018 Feb 14. (IBCSG 27-02) (Impact Factor 26.303).
358. Lee CK, Hudson M, Simes J, Ribic K, Bernhard J, Coates AS. When do patient reported quality of life indicators become prognostic in breast cancer? *Health Qual Life Outcomes* 2018 Jan 12;16(1):13. doi: 10.1186/s12955-017-0834-2. (IBCSG VI-IX and 13-15) (Impact Factor 2.143).
- 2017**
357. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *N Engl J Med* 2017;377(19):1836-1846. doi: 10.1056/NEJMoa1701830. (Trials VII, IX, 10-15, BIG 1-98) (Journal Impact Factor 72.406).
356. Wang XV, Cole B, Bonetti M, Gelber RD. Meta-STEPP with random effects. *Res Synth Methods* 2018;9(2):312-317. doi: 10.1002/jrsm.1288. Epub 2017 Dec 27. (Journal Impact Factor 3.018).
355. Lykkesfeldt AE, Iversen BR, Jensen MB, Ejlersen B, Giobbie-Hurder A, Reiter BE, Kirkegaard T, Rasmussen BB. Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. *Acta Oncol* 2018;57(1):67-73. doi: 10.1080/0284186X.2017.1404126. Epub 2017 Dec 4. (BIG 1-98) (Journal Impact Factor 3.156).

354. Alkner S, Jensen MB, Rasmussen BB, Bendahl PO, Fernö M, Rydén L, Mouridsen H, and Danish Breast Cancer Cooperative Group. Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98. *Breast Cancer Res Treat* 2017;166(2):481-490. doi: 10.1007/s10549-017-4416-0. Epub 2017 Aug 1. (BIG 1-98) (Impact Factor 3.626).
353. Procter M, Robertson C. Imputing missing quality of life data as covariate in survival analysis of the International Breast Cancer Study Group Trials VI and VII. *Communications in Statistics – Simulation and Computation* 2019;48(2):580-590. doi: 10.1080/03610918.2017.1390123. Epub 2017 Dec 15. (IBCSG VI, VII) (Journal Impact Factor 0.457).
352. Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy MJ, Von Moos R, Cortés J, Vidal MJ, Hennessy B, Walshe J, Amillano Parraga K, Ribí K, Bernhard J, Morales SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan MM, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. *Ann Oncol* 2018;29(3):661-668. doi: 10.1093/annonc/mdx772. Epub 2017 Dec 8. (IBCSG 42-12) (Journal Impact Factor 11.855).
351. Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribí K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM*, Goldhirsch A*; SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. *Co-last authors. *Lancet Oncol* 2018;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17. (IBCSG 35-07) (Journal Impact Factor 33.900).
350. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. *N Engl J Med* 2017;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. (IBCSG 39-11) (Journal Impact Factor 72.406).
349. Willis S, Sun Y, Abramovitz M, Fei T, Young B, Lin X, Ni M, Achua J, Regan MM, Gray KG, Gray R, Wang V, Long B, Kammler R, Sparano JA, Williams C, Goldstein LJ, Salgado R, Loi S, Pruneri G, Viale G, Brown M, Leyland-Jones B. High expression of FGD3, a putative regulator of cell morphology and motility, is prognostic of favorable outcome in multiple cancers. *JCO Precis Oncol* 2017 Oct 13. doi: 10.1200/PO.17.00009. (BIG 1-98).
348. Ribí K, Coates AS, Blacher L, Regan MM, Gelber RD, Bernhard J. Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al. *Qual Life Res* 2018;27(1):149-152. doi: 10.1007/s11136-017-1695-1. Epub 2017 Sep 5 (Commentary) (Impact Journal Factor 2.344).
347. Regan MM, Walley BA, Francis PA, Fleming GF, Láng I, Gómez HL, Colleoni M, Tondini C, Pinotti G, Salim M, Spazzapan S, Parmar V, Ruhstaller T, Abdi EA, Gelber RD, Coates AS, Goldhirsch A, Pagani O. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. *Ann Oncol* 2017;28(9):2225-2232. doi: 10.1093/annonc/mdx285. Epub 2017 Jul 29. (IBCSG 24-02 and 25-02) (Journal Impact Factor 11.855).
346. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thuerlimann B, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017. *Ann Oncol* 2017;28(8):1700–1712. doi: 10.1093/annonc/mdx308. Epub 2017 Jun 21. (special article) (Journal impact factor 11.855).
345. Francis PA. Adjuvant endocrine therapy for premenopausal women: Type and duration. *Breast* 2017;34(2017):S108-S111. doi: 10.1016/j.breast.2017.06.040. Epub 2017 Jun 29. (Commentary) (Journal Impact Factor 2.801).
344. Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribí K, Bernhard J, Luo W, Gómez HL, Burstein HJ, Parmar V, Torres R, Stewart J, Bellet M, Perelló A, Dane F, Moreira A, Vorobiof D, Nottage M, Price KN, Coates AS, Goldhirsch A, Gelber RD, Colleoni M, Fleming GF. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials. *J Clin Oncol* 2017;35(27):3113-3122. doi: 10.1200/JCO.2016.72.0946. Epub 2017 Jun 27. (IBCSG 24-02 and 25-02) (Journal Impact Factor 24.008).

343. Weischenfeldt KLH, Kirkegaard T, Rasmussen BB, Giobbie-Hurder A, Jensen M, Ejlertsen B, Lykkesfeldt AE. A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis. *Acta Oncol* 2017;56(9):1161-1167. doi: 10.1080/0284186X.2017.1324211. Epub 2017 May 10. (BIG 1-98) (Journal Impact Factor 3.156).
342. Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, Van de Velde CJH, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC. Long-term follow-up of the intergroup exemestane study. *J Clin Oncol* 2017;35(22):3507-2514. doi: 10.1200/JCO.2016.70.5640. Epub 2017 May 3. (IBCSG 16-98) (Journal Impact Factor 20.982).
341. Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thuerlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW; Trans-AIOG. HER2 status predicts for upfront AI benefits: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. *Eur J Cancer* 2017;79:129-138. doi: 10.1016/j.ejca.2017.03.033. Epub 2017 May 8. (BIG 1-98) (Journal impact factor 6.029).
340. Borgquist S, Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Láng I, Debled M, Ejlertsen B, von Moos R, Smith I, Coates AS, Goldhirsch A, Rabaglio M, Price KN, Gelber RD, Regan MM, Thuerlimann B. Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 Study. *J Clin Oncol* 2017;35(11):1179-1188. doi: 10.1200/JCO.2016.70.3116. Epub 2017 Feb 13. (BIG 1-98) (Journal impact factor 20.982).
339. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet* 2017;389(10075):1195-1205. doi: 10.1016/S0140-6736. Epub 2017 Feb 17. (IBCSG 28-02) (Journal impact factor 44.002).
338. Wapnir IL, Gelber S, Anderson SJ, Mamounas EP, Robidoux A, Martín M, Nortier JW, Geyer CE Jr, Paterson AH, Láng I, Price KN, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S; CALOR trial investigators. Poor prognosis after second locoregional recurrences in the CALOR trial. *Ann Surg Oncol* 2017;24(2):398-406. doi: 10.1245/s10434-016-5571-y. Epub 2016 Sep 23. (IBCSG 27-02) (Journal impact factor 3.151).

2016

337. Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA; the TEXT principal investigators. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. *Breast Cancer Res* 18:110, 2016. Doi: 10.1186/s13058-016-0771-8 (IBCSG 25-02) (Journal impact factor 5.211).
336. Colleoni M, Gray KP, Gelber S, Lang I, Thuerlimann B, Gianni L, Abdi E, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A. Low dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group (IBCSG) Trial 22-00. *J Clin Oncol* 34:3400-3408, 2016. (IBCSG 22-00) (Journal impact factor 20.982).
335. Baker SG, Bonetti M. Evaluating markers for guiding treatment. *J Natl Cancer Inst* (2016) 108 (9): djw101 doi:10.1093/jnci/djw101 First published online May 18, 2016 (6 pages). (BIG 1-98) (Journal impact factor 11.370).
334. Wang XV, Cole B, Bonetti M, Gelber RD. Meta-STEPP: subpopulation treatment effect pattern plot for individual patient data meta-analysis. *Stat in Med* 35:3704-3716, 2016. (Trials III, VI, IX) (Journal impact factor 1.533).
333. Karlsson P, Cole BF, Price KN, Gelber RD, Coates AS, Goldhirsch A, Castiglione M, Colleoni M, Gruber G, for the IBCSG. Timing of radiation therapy and chemotherapy after breast-conserving surgery for node-positive breast cancer: long-term results from International Breast Cancer Study Group Trials VI and VII. *Int J Radiat Oncol Biol Phys* 96:273-279, 2016. (IBCSG VI and VII) (Journal impact factor 4.258).
332. Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancelli G, Munzone E, Gelber RD, Regan MM, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. *Breast Cancer Res Treat* 158:323-331, 2016. (IBCSG 22-00) (Journal impact factor 4.085).
331. Chirgwin J, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, Láng I, Colleoni M, Thuerlimann B for the BIG 1-98 Collaborative and International Breast Cancer Study Groups Treatment adherence in the BIG 1-98 trial of tamoxifen, letrozole alone and in sequence. *J Clin Oncol* 34:2452-2459, 2016. (BIG 1-98) (Journal impact factor 20.982).

330. Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Price KN, Coates AS, Goldhirsch A, Gelber RD. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT trials. *J Clin Oncol* 34:2221-2231, 2016. (IBCSG 24-02 and 25-02) (Journal impact factor 18.443).
329. Pagani O, Regan MM, Francis PA. Are SOFT and TEXT results practice changing and how? *Breast* 27:122-125, 2016. (Commentary) (IBCSG 24-02 and 25-02) (Journal impact factor 2.381).
328. Phillips KA, Regan MM, Ribí K, Francis PA, Puglisi F, Bellet M, Spazzapan S, Karlsson P, Budman DR, Zaman K, Abdi EA, Domchek SM, Feng Y, Price KN, Coates AS, Gelber RD, Maruff P, Boyle F, Forbes JF, Ahles T, Fleming GF, Bernhard J. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. *Br J Cancer* 114:956-964, 2016. (IBCSG 24-02) (Journal impact factor 4.336).
327. Ribí K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Kerbrat P, Perelló A, Neven P, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates AS, Goldhirsch A, Price KN, Gelber RD, Regan MM, Fleming GF. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial. *J Clin Oncol* 34:1601-1610, 2016. (IBCSG 24-02) (Journal impact factor 18.443).
326. Bellet M, Gray KP, Francis PA, Lang I, Ciruelos E, Lluch A, Climent MA, Catalán G, Avella Mestre A, Bohn U, González-Martin A, Costa RF, Catalán R, Azaro A, Rajasekaran A, Morales J, Vázquez J, Fleming GF, Price KN, Regan MM, SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group. Twelve-month estrogen levels in premenopausal women with hormone-receptor positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the SOFT trial: the SOFT-EST substudy. *J Clin Oncol* 34:1584-1593, 2016. (IBCSG 24-02) (Journal impact factor 18.443).
325. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im, JH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial. *J Clin Oncol* 34:1034–1042, 2016. (IBCSG 36-07) (Journal impact factor 18.443).
324. Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thuerlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A. Hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. *J Clin Oncol* 34: 927-35, 2016 (IBCSG Trials I-V) (Journal impact factor 18.443).
323. Lazar AA, Bonetti M, Cole BF, Yip W, Gelber RD. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP. *Clinical Trials* 13:169-179, 2016. (Journal impact factor 1.925).
322. Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Rothé F, Laíos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C. The genomic grade assay compared with Ki67 to determine risk of distant breast cancer recurrence. *JAMA Oncol* 2:217-224, 2016 (BIG 1-98) (Journal does not yet have an impact factor).
321. Metzger-Filho O, de Azambuja E, Procter M, Krieger M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart M, Gelber RD for the HERA Study Team. Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. *Breast Cancer Res Treat* 155:127-132, 2016 (IBCSG 28-02) (Journal impact factor 3.940).

2015

320. Butow P, Brown R, Aldridge J, Juraskova I, Zoller P, Boyle F, Wilson M, Bernhard J. Can consultation skills training change doctors' behaviour to increase involvement of patients in making decisions about standard treatment and clinical trials: a randomized controlled trial. *Health Expect* 18:2570-2583, 2015 (IBCSG 33-03) (Journal impact factor 2.852).
319. Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair OM, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber RD, Goldhirsch A, Korde L, Azim HA Jr, Partridge AH. Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? *Breast*. 24:201-207, 2015 (IBCSG 48-14) (Journal impact factor 2.381).

318. Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thuerlimann B, Harvey V, Neven P, Arnould L, Maibach R, Price KN, Coates AS, Goldhirsch A, Gelber RD, Pagani O, Viale G, Rae JM, Regan MM; BIG 1-98 Collaborative Group. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. *Breast Cancer Res Treat* 154:543-555, 2015. (BIG 1-98) (Journal impact factor 3.940).
317. Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thuerlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M; International Breast Cancer Study Group and the BIG 1-98 Collaborative Group. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. *Ann Oncol* 26:2442-2449, 2015. (BIG 1-98) (Journal impact factor 7.040).
316. Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Szöke J, Doimi F, Villani L, Pizzolitto S, Öhlschlegel C, Sessa F, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G; SOFT and TEXT Investigators and International Breast Cancer Study Group. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. *Breast Cancer Res Treat* 154:275-286, 2015. (IBCSG 24-02 and 25-02) (Journal impact factor 3.940).
315. Regan MM. Predicting benefit of endocrine therapy for early breast cancer. *Breast Nov 1 Suppl 2*:S129-31, 2015. (IBCSG 24-02 and 25-02, BIG 1-98) (Journal impact factor 2.381).
314. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet* 386:1341-1352, 2015. (BIG 1-98) (Journal impact factor 45.217).
313. Metzger Filho O*, Giobbie-Hurder A*, Mallon EA, Gusterson B, Viale G, Winer EP, Thuerlimann B, Gelber RD, Colleoni M, Ejlertsen B, Debled M, Price KN, Regan MM, Coates AS, Goldhirsch A. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. *Co-first authors. *J Clin Oncol* 33:2772-2779, 2015. (BIG 1-98) (Journal impact factor 18.428).
312. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thuerlimann B, Senn HJ; Panel members. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol* 26: 1533-1546, 2015. (special article) (Journal impact factor 7.040).
311. Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérrez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. *Eur J Cancer* 51:1481-1489, 2015 (IBCSG 20-98) (Journal impact factor 5.417).
310. Bernhard, J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. *Lancet Oncol* 16:848-858, 2015. (IBCSG 24-02 and 25-02) (Journal impact factor 24.725).
309. Goldhirsch A, Colleoni M, Regan M. Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease. *Ecanermedicalscience*. 2015 Jun 9;9:544. eCollection 2015. (Commentary)
308. Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thuerlimann B, Lyng MB, Ditzel HJ, Harvey V, Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM; on behalf of the BIG 1-98 Collaborative Group. CYP19A1 Polymorphisms and clinical outcomes in postmenopausal women with hormone-receptor positive breast cancer in the BIG 1-98 trial. *Breast Cancer Res Treat* 151:373-384, 2015. (BIG 1-98) (Journal impact factor 4.469).
307. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; the POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med* 5:372:923-932, 2015. (IBCSG 34-05) (Journal impact factor 51.658).

306. Francis PA*, Regan MM*, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer Jr CE, Walley BA, Coleman RC, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD for the SOFT investigators and the International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. *Co-first authors. *N Engl J Med* 372:436-446, 2015. (IBCSG 24-02) (Journal impact factor 51.658).

305. Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PER, Shepherd LE, Goss PE. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. *J Clin Oncol* 33:265-271, 2015 (IBCSG 30-04) (Journal impact factor 17.879).

2014

304. Sieuwerts AM, Willis S, Burns MB, Look MP, Gelder ME, Schlicker A, Heideman MR, Jacobs H, Wessels L, Leyland-Jones B, Gray KP, Foekens JA, Harris RS, Martens JW. Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers. *Horm Cancer* 5:405-413, 2014. (BIG 1-98) (Journal impact factor 4.907).

303. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribí K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; the TEXT and SOFT Investigators and the International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med* 371:107-118, 2014. (IBCSG 24-02 and 25-02) (Journal impact factor 51.658).

302. Senkus E, Gomez H, Dirix L, Jerusalem G, Murray E, Van Tienhoven G, Westenberg AH, Bottomley A, Rapon J, Bogaerts J, Di Leo A, Nešković-Konstantinović Z. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. *Psychooncology* 23:173-182, 2014. (IBCSG 29-03) (Journal impact factor 3.506).

301. Decensi A, Sun Z, Guerrieri-Gonzaga A, Thuerlimann B, McIntosh C, Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman K, Johansson H, Price KN, Gelber RD, Goldhirsch A, Coates AS, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. *Breast Cancer Res Treat* 144:321-329, 2014. (BIG 1-98) (Journal impact factor 4.469).

300. McCullough AE, Dell'Orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. *Breast Cancer Res Treat* 143:485-492, 2014. (IBCSG 36-07) (Journal impact factor 4.469).

299. Aebi S, Gelber S., Anderson SJ, Láng I, Robidoux A, Martín M, Nortier JWR, Paterson A, Rimawi MF, Baena Cañada JM, Thuerlimann B, Murray E, Mamounas EP, Geyer CE, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL on behalf of the CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. *Lancet Oncol* 15:156-163, 2014. (IBCSG 27-02) (Journal impact factor 25.12).

298. Huober J, Cole BF, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlersen B, Bonnefoi H, Forbes JF, Neven P, Lang I, Smith I, Wardley A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Gelber RD, Thuerlimann B, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. *Breast Cancer Res Treat* 143:159-69, 2014. (BIG 1-98) (Journal impact factor 4.469).

2013

297. Pagani O, Gelber S, Colleoni M, Price KN, Simoncini E. Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93. *Breast Cancer Res Treat* 142: 455-459, 2013. (IBCSG 13-93 and 14-93) (Journal impact factor 4.469).

296. Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA for the IBCSG and SOFT and TEXT investigators. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. *The Breast* 22:1094-1100, 2013. (IBCSG 24-02 and 25-02) (Journal impact factor 1.967).

295. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. *Lancet* 382:1021-1028, 2013. (IBCSG 28-02) (Journal impact factor 39.060).

294. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder R, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Cardoso F for the IBCSG. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from International Breast Cancer Study Group Trials VIII and IX. *J Clin Oncol* 31:3083-3090, 2013. (IBCSG VIII and IX) (Journal impact factor 18.038).
293. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thuerlimann B, Senn H-J, panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol* 24:2206-2223, 2013. (special article) (Journal impact factor 7.384).
292. Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. *J Clin Oncol*, 31:2963:2969, 2013. (BIG 1-98) (Journal impact factor 18.038).
291. Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thuerlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber RD, Piccart-Gebhart M, Viale G, Di Leo A. Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial. *Ann Oncol* 24: 1203-1211, 2013. (IBCSG 20-98) (Journal impact factor 6.425).
290. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PER, Lang I, Elliott C, Gelmon KA, Chapman JAW, and Shepherd LE. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—A randomized controlled phase III trial. *J Clin Oncol* 31:1398-1404, 2013 (IBCSG 30-04) (Journal impact factor 18.372).
289. Galimberti V, Cole BF, Zurrada S, Viale V, Luini, A, Veronesi P, Paola Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, PriceKN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U for the IBCSG Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. *Lancet Oncol* 14: 297-305, 2013 (IBCSG 23-01) (Journal impact factor 22.589).
288. Crivellari D, Gray KP, Dellapasqua S, Puglisi F, Ribí K, Price KN, Láng I, Gianni L, Spazzapan S, Pinotti G, Lüthi JM, Gelber RD, Regan MM, Colleoni M, Castiglione-Gertsch M, Maibach R, Rabaglio M, Coates AS, Goldhirsch A for the IBCSG. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: the CASA randomized trial. *The Breast* 22:130-137, 2013 (IBCSG 32-05) (Journal impact factor 2.491).
287. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 *J Clin Oncol* 31:860-867, 2013 (IBCSG 20-98) (Journal impact factor 18.372).
286. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, WardleyA, Lichinitser M, Sanchez RIL, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) *Lancet Oncol* 14:244-248, 2013. (IBCSG 28-02) (Journal impact factor 22.589).
285. Bernhard J, Aldridge J, Butow PN, Zoller P, Brown R, Smith A, Juraskova I. Patient–doctor agreement on recall of clinical trial discussion across cultures. *Ann Oncol* 24: 391-397, 2013. (Trial 33-03) (Journal impact factor 6.425).
284. Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensch N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart MJ, Peccatori FA. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: A multicenter retrospective study *J Clin Oncol* 31:73-79, 2013. (meta-analysis) (Journal impact factor 18.372).

2012

283. Coates AS, Millar EKA, O'Toole SA, Molloy TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z, Castiglione-Gertsch M, Gusterson B, Musgrove EA, Sutherland RL. Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX, *Breast Cancer Res* 14:R143, 2012 (Trials VIII and IX). (Journal impact factor 5.25).

282. Bernhard J, Butow P, Aldridge J, Juraskova I, Ribi K, Brown R. Communication about standard treatment options and clinical trials: can we teach doctors new skills to improve patient outcomes? *Psycho-Oncology* 21:1265-1274, 2012 (Trial 33-03) (Journal impact factor 3.339).
281. Ewertz M, Gray KP, Regan MM, Ejilertsen B, Price KN, Thuerlimann B, Bonnefoi H, Forbes JFF, Paridaens R, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith I, Coates AS, Goldhirsch A, Mouridsen H for BIG 1-98 Collaborative and International Breast Cancer Study Groups. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 Trial. *J Clin Oncol* 30:3967-3975, 2012 (BIG 1-98) (Journal impact factor 18.372).
280. Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Öhlschlegel C, Price KN, Gelber RD, Regan MM, Thuerlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. *Ann Oncol* 23:2843-2851, 2012. (Trials I-IX, 11-14) (Journal impact factor 6.425).
279. Karlsson P, Cole BF, Chua BH, Price KN, Lindtner J, Collins JP, Kovács A, Thuerlimann B, Crivellari D, Castiglione-Gertsch M, Forbes JF, Gelber RD, Goldhirsch A, Gruber G for the IBCSG. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. *Ann Oncol* 23: 2852-2858, 2012. (Trials I-IX, 11-14) (Journal impact factor 6.425).
278. Ribi K. Cognitive complaints in women with breast cancer: cross-cultural considerations. *Ann Oncol* 23: 2475-2478, 2012 (editorial) (Journal impact factor 6.452).
277. Dellapasqua S, Bagnardi V, Regan MM, Rotmensz N, Mastropasqua MG, Viale G, Maiorano E, Price KN, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Colleoni M. A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer, *The Breast* 21:621-628, 2012 (Trial VIII) (Journal impact factor 2.491).
276. Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth K, Quinaux E, Buyse M, Dolci S, De Azambuja E, Hainaut P, Dell'Orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Di Leo A, Olivier M. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane based adjuvant therapy: results from the BIG 02-98 phase III trial. E-published May 2012, *Breast Cancer Res* 14:R70 (Trial 02-98) (Journal impact factor 5.25).
275. Zaman K, Thuerlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). *Ann Oncol* 23:1474-1481, 2012. (BIG 1-98) (Journal impact factor 6.452).
274. Coates AS, Colleoni M, Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal A breast cancer? *J Clin Oncol* 30:1260-1263, 2012 (Commentary) (Journal impact factor 18.970).
273. Ribi K, Aldridge J, Phillips K-A, Thompson A, Harvey V, Thuerlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J for the IBCSG. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. *British J Cancer* 106:1618-1625, 2012. (BIG 1-98) (Journal impact factor 4.831).
272. Ejilertsen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, Lykkesfeldt AE, Müller S, Gelber RD, Price KN, Rasmussen BB, Viale G, Mouridsen H for the Danish Breast Cancer Cooperative Group, the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. *Ann Oncol* 23: 1138–1144, 2012 (BIG 1-98) (Journal impact factor 6.452).
271. Regan MM*, Leyland-Jones B*, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi MO, Thuerlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; on behalf of the Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. *J Natl Cancer Inst* 104:441-451, 2012. *Co-first authors (BIG 1-98) (Journal impact factor 14.697).
270. Brown RF, Butow PN, Wilson-Genderson M, Bernhard J, Ribi K, Juraskova I. Meeting the Decision-Making Preferences of Patients With Breast Cancer in Oncology Consultations: Impact on Decision-Related Outcomes. *J Clin Oncol* 30:857-862, 2012. (Trial 33-03) (Journal impact factor 18.970).
269. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. *J Clin Oncol* 30:709-717, 2012 (Trial 16-98) (Journal impact factor 18.970).

268. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang T-W, Horváth Z, Coccia-Portugal M, Domont J, Tseng L-M, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Puztai L, Untch M, Gelber RD, Piccart-Gebhart M, on behalf of the NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. *The Lancet* 379:633-664, 2012. (Trial 37-07) (Journal impact factor 33.63).

267. Chirgwin J, Sun Z, Smith I, Price KN, Thuerlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. *Breast Cancer Res Treat* 131:295-306, 2012. (BIG 1-98) (Journal impact factor 4.86).

2011

266. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial *Lancet Oncology* 12:236-44, 2011. (Trial 28-02) (Journal impact factor 17.76).

265. Dowsett M, Nielsen TO, A'hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. *J Natl Cancer Inst* 103:1656-1664, 2011. (Commentary) (Journal impact factor 14.697).

264. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thuerlimann B, for the members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. *Lancet Oncology* 12:1101-1108, 2011 plus webappendix. (BIG 1-98) (Journal impact factor 17.76).

263. Brown RF, Butow PN, Juraskove I, Ribi K, Gerber D, Bernhard J, Tattersall MH. Sharing decisions in breast cancer care: Development of the Decision Analysis System for Oncology (DAS-O) to identify shared decision making during treatment consultations. *Health Expect* 14:29-37, 2011. (Trial 33-03) (Journal impact factor 2.32).

262. Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Long term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. *Ann Oncol* 22:2216-2226, 2011. (Trial VIII) (Journal impact factor 6.45).

261. Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thuerlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. *Ann Oncol* 22:2201-2207, 2011. (BIG 1-98) (Journal impact factor 6.45).

260. Francis PA. Optimal adjuvant therapy for very young breast cancer patients. *The Breast* 20:297-302, 2011. (Review) (Journal impact factor 2.09).

259. Pagani O, Partridge A, Korde L, Badve S, Bartlett J, Albain K, Gelber R, Goldhirsch A. Pregnancy after breast cancer: if you wish, ma'am. *Breast Cancer Res Treat* 129:309-317, 2011. (Review) (Journal impact factor 4.86).

258. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes C, Roche H, Tokuda Y, de Vries EGE, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials. *J Clin Oncol* 29:3214-3223, 2011. (Meta-analysis includes Trial 15-95) (Journal impact factor 18.97).

257. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet* 378:771-784, 2011. (Meta-analysis includes Trial 13-93) (Journal impact factor 33.63).

256. Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. *Ann Oncol* 22:1981-1987 2011. (Trial IX) (Journal impact factor 6.45).
255. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thuerlimann B, Senn H-J, panel members. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol* 22: 1736-1747, 2011. (Commentary) (Journal impact factor 6.4).
254. Regan MM, Price KN, Giobbie-Hurder A, Thuerlimann B, Gelber RD for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting Breast International Group (BIG) 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. *Breast Cancer Res* 13:209, 2011. (BIG 1-98) (Journal impact factor 5.3).
253. Phillips KA, Ribí K, Fisher R. Do aromatase inhibitors have adverse effects on cognitive function? *Breast Cancer Res* 13: 203, 2011 (review) (Journal impact factor 5.3)
252. Karlsson P, Cole BF, Colleoni M, Roncadin M, Chua B, Murray E, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gruber G for the IBCSG. Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy. *Int J Rad Onc Biol Phys* 80:398–402, 2011. (Trials VI, VII, IX) (Journal impact factor 4.59).
251. Colleoni M, Giobbie-Hurder A, Regan MM, Thuerlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study *J Clin Oncol* 29:1117-1124, 2011. (BIG 1-98) (Journal impact factor 17.8).
250. Smith A, Juraskova I, Butow P, Miguel C, Lopez AL, Chang S, Brown R, Bernhard J. Sharing vs. caring—The relative impact of sharing decisions versus managing emotions on patient outcomes. *Patient Educ Couns.* 82 233–239, 2011. (Trial 33-03) (Journal impact factor 2.0)
249. Phillips KA, Aldridge J, Ribí K, Sun Z, Thompson A, Harvey V, Thuerlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy *Breast Cancer Res Treat* 126:221-226, 2011. (BIG 1-98) (Journal impact factor 4.7)
248. Azim HA, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, Peccatori FA. Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies *Eur J Cancer* 47: 74-83, 2011. (meta-analysis) (Journal impact factor 4.1).
- 2010**
247. Colleoni M, Giobbie-Hurder A. Benefits and adverse effects of endocrine therapy. *Ann Oncol* 21 (Suppl 7): vii107–vii111, 2010. (Review) (Journal impact factor 5.6)
246. Lazar AA, Cole BF, Bonetti M, Gelber RD. Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: Subpopulation Treatment Effect Pattern Plot. *J Clin Oncol* 28:4539-4544, 2010 (Statistical) (Journal impact factor 17.8).
245. Phillips KA, Ribí K, Sun Z, Stephens A, Thompson A, Harvey V, Thuerlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. *The Breast* 19:388-395, 2010 (BIG 1-98) (Journal impact factor 2.1).
244. Zhang, JJ and Wang, M, Latent class joint model of ovarian function suppression and DFS for premenopausal breast cancer patients. *Stat in Med* 29: 2310–2324, 2010 (Statistical, Trial VIII) (Journal impact factor 2.0).
243. Gunnarsdóttir K, Jensen M-B, Zahrieh D, Gelber RD, Knoop A, Bonetti M, Mouridsen H, Ejlertsen B. CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. *Breast Cancer Res Treat* 123:163-169, 2010 (Statistical collaboration) (Journal impact factor 4.7).
242. Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thuerlimann B, Price KN, Holmberg SB, Crivellari D, Coates AS, Goldhirsch A. Adjuvant!® Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. *Breast Cancer Res Treat* 123:303-310, 2010 (Trial 11-93) (Journal impact factor 4.7).

241. Rabaglio M, Ruepp B, for the STP Steering Committee. Death due to liver failure during endocrine therapy for premenopausal breast cancer. *ACTA Oncologica* 49:874-876, 2010 (Trials 24-02 and 25-02) (Journal impact factor 2.7).
240. Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS, Gusterson BA. Classical Cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. *J Clin Oncol* 28:2966-2973, 2010. (Trials VIII-IX) (Journal impact factor 17.2).
239. Maiorano E, Regan MM, Viale G, Mastropasqua MG, Colleoni M, Castiglione-Gertsch M, Price KN, Gelber RD, Goldhirsch A, Coates AS. Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. *Breast Cancer Res Treat* 121:211-218, 2010. (Trials VIII and IX) (Journal impact factor 5.7).
238. Antonov J, Popovici V, Delorenzi M, Wirapati P, Baltzer A, Oberli A, Thuerlimann B, Giobbie-Hurder A, Viale G, Altermatt HJ, Aebi S, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. *BMC Cancer* 10:37, 2010. (BIG 1-98) (Journal impact factor 3.1).
237. Butow PN, Juraskova I, Chang S, Lopez AL, Brown R, Bernhard J. Shared decision making coding systems; How do they compare in the oncology context? *Patient Educ Couns* 78:261-268, 2010 (Trial 33-03) (Journal impact factor 1.9).
236. de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JPA, Vicente M, Giuliani R, Nordenskjöld B, Gutiérrez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Angelo Di Leo A, Piccart-Gebhart M. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. *Breast Cancer Res Treat* 119:145-153, 2010. (Trial 20-98) (Journal impact factor 5.7).
235. Viale G, Giobbie-Hurder A, Gusterson BA, Maiorano E, Mastropasqua MG, Sonzogni A, Mallon E, Colleoni M, Castiglione-Gertsch M, Regan MM, Price KN, Brown RW, Golouh R, Crivellari D, Karlsson P, Öhlschlegel C, Gelber RD, Goldhirsch A, Coates AS. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. *Ann Oncol* 21:245-254, 2010 (Trials VIII-IX) (Journal impact factor 4.9).
233. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. *J Clin Oncol* 28:509-518, 2010 (BIG 1-98) (Journal impact factor 17.2).
- 2009**
234. Zhang JJ, Wang M. An accelerated failure time mixture cure model with masked event. *Biometrical Journal* 51:932-945, 2009. (Trial VIII) (Journal impact factor 1.1)
232. Gelber RD, Gelber S for the International Breast Cancer Study Group (IBCSG) and Breast International Group (BIG). Facilitating consensus by examining patterns of treatment effect. *The Breast* 18 (Supp 3):S2-S8, 2009 (Commentary) (Journal impact factor 2.2).
231. Joerger M, Thuerlimann B. Update of the BIG 1-98 trial: Where do we stand? *The Breast* 18 (Supp 3):S78-S82, 2009 (BIG 1-98) (Journal impact factor 2.2).
230. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thuerlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. *Ann Oncol* 20: 1489-1498, 2009 (BIG 1-98) (Journal impact factor 4.9).
229. Desmedt C, Giobbie-Hurder A, Neven P, Paridaens R, Christiaens MR, Smeets A, Lallemand F, Haibe-Kains B, Viale G, Gelber RD, Piccart M, Sotiriou C. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. *BMC Medical Genomics* 2:40, 2009 (BIG 1-98).
228. Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thuerlimann B, Collins J, Fey MF, Coates AS, Goldhirsch A, for the IBCSG. Patterns of recurrence of early breast cancer according to estrogen receptor status: A therapeutic target for a quarter of a century. *Breast Cancer Res Treat* 117:319-324, 2009 (Trials III and IV) (Journal impact factor 5.7).

227. BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. *N Engl J Med* 361:766-776, 2009 (BIG 1-98) (Journal impact factor 50.0).
226. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thuerlimann B, Senn H-J & panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. *Ann Oncol* 20: 1319-1329, 2009 (Journal impact factor 4.9).
225. Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN, Goldhirsch A for the International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. *Ann Oncol* 20:1344-1351, 2009 (Trial 15-95) (Journal impact factor 4.9).
224. Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, Perez EA, Hartmann LC. Menstrual cycle and surgical treatment of breast cancer: Findings from the NCCTG N9431 study. *J Clin Oncol* 27:3620-3626, 2009 (Trial 21-99) (Journal impact factor 17.2).
223. Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Lindtner J, Thuerlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A, for the International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. *Breast Cancer Res Treat* 116:491-500, 2009 (Trials VII and 12-93) (Journal impact factor 4.5).
222. Giobbie-Hurder A, Price KN, Gelber RD for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. *Clinical Trials* 6:272-286, 2009. (BIG 1-98) (Journal impact factor 1.9)
221. Sun Z, Goldhirsch A, Price KN, Colleoni M, Ravaioli A, Simoncini E, Campbell I, Gelber RD, Towler M. Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer. *The Breast* 18:84-88, 2009. (BIG 1-98) (Journal impact factor 1.7).
220. Bonetti M, Zahrieh D, Cole BF, Gelber RD. A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data. *Statist Med* 28:1255-1268, 2009. (Journal impact factor 1.5).
219. Ruhstaller T, von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, Koeberle, Mueller U, Markus Hoefliger M, Hess D, Boehme C, Thuerlimann B. Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. *Oncology* 76:142-148, 2009. (BIG 1-98) (Journal impact factor 4.4).
218. Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A. Second non-breast primary cancer following adjuvant therapy for early breast cancer: A report from the International Breast Cancer Study Group. *Eur J Cancer* 45:561-571, 2009. (Trials III, VII, 12, 14) (Journal impact factor 4.5).
217. Thuerlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. *Breast Cancer Res Treat* 113:137-144, 2009. (Journal impact factor 4.5).

2008

216. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Öhlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thuerlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. *J Clin Oncol* 26:5569-5575, 2008. (BIG 1-98) (Journal impact factor 15.5).
215. Wapnir IL, Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Mamounas EP, Wolmark N. Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. *Ann Surg Oncol* 15:3227-3231, 2008 (Trial 27-02) (Journal impact factor 3.92).
214. Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B, Gnant M, Gutierrez J, Láng I, Crown JP, Piccart-Gebhart M; on behalf of the BIG 02-98 Collaborative Group. Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial. *Ann Oncol* 19:1837-1841, 2008. (Trial 20-98) (Journal impact factor 4.9).

213. Fleming GF and Francis P. Commentary on: Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. *Breast Diseases: A Year Book Quarterly* 19:278-279, 2008. (Trial 24-02).
212. Gruber G, Cole BF, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Thuerlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Price KN, Goldhirsch A, Viale G, Gusterson BA, for the International Breast Cancer Study Group. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. *Ann Oncol* 19:1393-1401, 2008. (Trial VI) (Journal impact factor 4.9).
211. Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N. A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. *Clinical Breast Cancer* 8:287-292, 2008. (Trial 27-02).
210. Regan MM, Pagani O, Walley B, Torrissi R, Perez EA, Francis P, Fleming GF, Price KN, Thuerlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD for the SOFT/TEXT/PERCHE Steering Committee and the International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? *Ann Oncol* 19:1231-1241, 2008. (Trials 25-02, 26-02, 11-93) (Journal impact factor 5.2).
209. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thuerlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. *J Clin Oncol* 26:3006-3014, 2008. (Trials I-15) (Journal impact factor 13.6).
208. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A for the HERA Study Team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. *Ann Oncol* 19: 1090-1096, 2008. (Trial 28-02) (Journal impact factor 5.2).
207. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. *Ann Oncol* 19:877-882, 2008. (Trial 19-01) (Journal impact factor 5.2).
206. Holmberg L, Iversen O-E, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpa J, on behalf of the HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors *J Natl Cancer Inst* 100:475-482, 2008. (Trial 17-98) (Journal impact factor 15.3).
205. Crivellari D, Sun Z, Coates AS, Price KN, Thuerlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. *J Clin Oncol* 26:1972-1979, 2008. (BIG 1-98) (Journal impact factor 13.6).
204. Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates AS, Price KN, Gusterson BA, Viale G, for the International Breast Cancer Study Group. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. *Ann Oncol* 19:660-668, 2008. (Trials VIII-IX) (Journal impact factor 5.2).
203. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Öhlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson B, Coates AS, for the IBCSG. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors—International Breast Cancer Study Group. *J Clin Oncol* 26:1404-1410, 2008. (Trials VIII-IX) (Journal impact factor 13.6).
202. Viale G, Regan MM, Mastropasqua MG, Maiorano E, Maffini F, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Öhlschlegel C, Gusterson B, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS, for the IBCSG. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemo-endocrine therapy for node-negative breast cancer. *J Natl Cancer Inst* 100:207-212, 2008. (Trials VIII-IX) (Journal impact factor 15.3).

201. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, and Piccart-Gebhart M, for the BIG 02-98 Collaborative Group. Adjuvant Chemotherapy with Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02-98 Randomized Trial. *J Natl Cancer Inst* 100:121-133, 2008. (Trial 20-98) (Journal impact factor 15.3).

200. Bernhard J, Zahrieh D, Zhang JJ, Martinelli G, Basser R, Hüry C, Forbes JF, Aebi S, Yeo W, Thuerlimann B, Green MD, Colleoni M, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS, for the International Breast Cancer Study Group (IBCSG). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high risk primary breast cancer. *Br J Cancer* 98:25-33, 2008. (Trial 15-95) (Journal impact factor 4.5).

199. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thuerlimann B, Coates AS, Viale G for the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant letrozole vs. tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. *Lancet Oncol* 9:23-28, 2008. (BIG 1-98) (Journal impact factor 10.1).

198. Gianni L, Cole BF, Panzini I, Snyder R, Holmberg SB, Byrne M, Crivellari D, Colleoni M, Aebi S, Simoncini E, Pagani O, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS, Ravaioli A. Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. *Support Care Cancer* 16:67-74, 2008. (Trials 13-14) (Journal impact factor 1.9).

2007

197. Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, Thuerlimann B, Mauriac L, Forbes JF, Paridaens R, Gelber RD, Colleoni M, Smith I, Price KN, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of trial BIG 1-98. *J Clin Oncol* 25:5715-5722, 2007. (BIG 1-98) (Journal impact factor 13.6).

196. Dellapasqua S, Colleoni M, Castiglione M, Goldhirsch A. New criteria for selecting elderly patients for breast cancer adjuvant treatment studies. *Oncologist*. 12:952-959, 2007. (Review) (Journal impact factor 5.2).

195. Baumann CK, Castiglione-Gertsch M. Estrogen receptor modulators and down regulators optimal use in postmenopausal women with breast cancer. *Drugs* 67:2335-2353, 2007. (Commentary) (Journal impact factor 4.5).

194. Rabaglio M, Aebi S, Castiglione-Gertsch M. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St. Gallen Conference. *Lancet Oncol* 8:940-949, 2007. (Review article) (Journal impact factor 10.1).

193. Regan MM, Gelber RD. Using clinical trial data to tailor adjuvant treatments for individual patients. *The Breast* 16: S98-S104, 2007. (Journal impact factor 1.7).

192. Koeberle D, Thuerlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. *Breast Cancer Res and Treat* 105 Suppl 1:55-66, 2007. (BIG 1-98) (Journal impact factor 4.7).

191. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Oehlschlegel C, Thuerlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal women with early breast cancer: BIG 1-98. *J Clin Oncol*, 25:3846-3852, 2007. (BIG 1-98) (Journal impact factor 13.6).

190. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI, *Eur J Cancer* 43:1646-1653, 2007. (Trials V and VI) (Journal impact factor 3.7).

189. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thuerlimann B, Senn HJ, and panel members. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. *Ann Oncol* 18:1133-1144, 2007. (Commentary) (Journal impact factor 5.2).

188. International Breast Cancer Study Group. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) trials 13-93 and 14-93. *Ann Oncol* 18:1177-1184, 2007. (Journal impact factor 5.2).

187. Crivellari D, Aapro M, Leonard R, von Minckwitz G, Brain E, Goldhirsch A, Veronesi A, and Muss H. Breast cancer in the elderly. *J Clin Oncol* 25:1882-1890, 2007. (Review article) (Journal impact factor 11.8).
186. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer, MJ, Pater JL. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. *J Clin Oncol* 25:2006-2011, 2007. (Trial 19-01) (Journal impact factor 11.8).
185. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. *Lancet* 369: 1711–1723, 2007. (Trial VIII) (Journal impact factor 23.4).
184. Karlsson P, Cole BF, Price, KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thuerlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. *J Clin Oncol* 25:2019-2026, 2007. (Trials I-IX) (Journal impact factor 11.8).
183. Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thuerlimann B, Paridaens R, Monnier A, Láng I, Wardley A, Nogaret J-M, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A for the BIG 1-98 Collaborative and the International Breast Cancer Study Groups. Predictors of early relapse in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial. *Ann Oncol* 18: 859–867, 2007. (BIG 1-98) (Journal impact factor 4.3).
182. Fleming GF and Francis P. Commentary on: Adjuvant goserelin in premenopausal patients with early breast cancer: Results from the ZIPP study. *Breast Diseases: A Year Book Quarterly* 18:99-100, 2007. (Trial 24-02)
181. Piccart M, Goldhirsch A, Wood W, Pritchard K, Baselga J, Reaby L, Kössler I, Kyriakides S, Norton L, Coates A. Keeping faith with trial volunteers. *Nature* 446:137-138, 2007. (Commentary) (Journal impact factor 29.3).
180. Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thuerlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS & Goldhirsch A for the IBCSG. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. *Ann Oncol* 18:701-708, 2007. (Trials VIII, IX, 11-15) (Journal impact factor 4.3).
179. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. *Lancet* 369:559-570, 2007. (Trial 16-98) (Journal impact factor 23.4).
178. Coates AS, Keshaviah A, Thuerlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jacobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. *J Clin Oncol* 25: 486-492, 2007. (BIG 1-98) (Journal impact factor 11.8).
177. Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thuerlimann B, Price KN, Goldhirsch A, Coates AS. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients—the International Breast Cancer Study Group Trial VIII. *J Clin Oncol* 25:263-270, 2007. (Journal impact factor 11.8).
176. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ for the HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. *Lancet* 369:29-36, 2007. (Trial 28-02) (Journal impact factor 23.4).

2006

175. Goldhirsch A, Coates AS, Gelber RD, Glick JH, B. Thuerlimann B, Senn HJ, on behalf of the St Gallen Expert Panel Members: First—select the target: better choice of adjuvant treatments for breast cancer patients. *Ann Oncol* 17: 1772-1776, 2006. (Journal impact factor 4.3).

174. Regan MM, Viale G, Mastropasqua, MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurkula M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B for the IBCSG. Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. *J Natl Cancer Inst* 98:1571-1581, 2006. (Trials VIII-IX) (Journal impact factor 15.2).
173. Castiglione-Gertsch M. Adjuvant treatment of breast cancer: sequence and duration of hormonal therapy. *Ann Oncol* 17 (Suppl 10): x51-x53, 2006. (Commentary) (Journal impact factor 4.3).
172. Szwarc S, Bonetti M. Modelling menstrual status during and after adjuvant treatment for breast cancer. *Statist Med* 25:3534-3547, 2006. (Trial VIII) (Journal impact factor 1.5).
171. Aebi S, Castiglione M. The enigma of young age. *Ann Oncol* 17:1475-1477, 2006. (editorial) (Journal impact factor 4.3).
170. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez E, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. *Breast Cancer Res Treat* 99:295-300, 2006. (Trial 19-01) (Journal impact factor 4.6).
169. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A for the IBCSG. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). *Ann Oncol* 17:935-944, 2006. (Trials I-IX) (Journal impact factor 4.3).
168. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: IBCSG Trial 13-93. *J Clin Oncol* 24:1332-1341, 2006. (Journal impact factor 9.8).
167. Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS, Ravioli A for the IBCSG. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group Trials. *Cancer* 106:505-513, 2006. (Trials III, IV, VII, IX, 11-93, 12-93, 14-93) (Journal impact factor 4.4).
166. International Breast Cancer Study Group. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. *J Clin Oncol* 24:337-344, 2006. (Journal impact factor 9.8).
165. International Breast Cancer Study Group. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. *J Clin Oncol* 24:370-378, 2006. (Journal impact factor 9.8).

2005

164. BIG 1-98 Collaborative. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. *N Engl J Med* 353:2747-2757, 2005. (BIG 1-98) (Journal impact factor 38.6).
163. Dellapasqua S, Castiglione-Gertsch M. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: Standards and not. *The Breast* 14:555-563, 2005. (Commentary) (Journal impact factor 0.8).
162. Regan MM, Gelber RD. Predicting response to systemic treatments: learning from the past to plan for the future. *The Breast* 14:582-593, 2005. (Trials VII and IX) (Journal impact factor 0.8).
161. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD for the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 353:1659-1672, 2005. (Trial 28-02) (Journal impact factor 38.6).
160. Price KN, Goldhirsch A for the IBCSG. Clinical trial update: International Breast Cancer Study Group. *Breast Cancer Res* 7:252-254, 2005. (Commentary) (Journal impact factor 3.0).
159. Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam C-M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Carbone A, Thuerlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A, for the IBCSG. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: Long-term observations from International Breast Cancer Study Group Trial VI. *J Clin Oncol* 23:7089-7097, 2005. (Trial VI) (Journal impact factor 9.8).

158. Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, Goldhirsch A for the International Breast Cancer Study Group. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. *Lancet* 366:1108-1110, 2005. (Trials I, II, V, VI) (Journal impact factor 21.7).
157. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thuerlimann B, Senn HJ. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. *Ann Oncol* 16:1569-1583, 2005. (Commentary) (Journal impact factor 4.3).
156. Cole BF, Bonetti M, Zaslavsky AM, Gelber RD. A multistate Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness. *Stat Med* 24:2317-2334, 2005. (Trial VII) (Journal impact factor 1.4).
155. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 365:1687-1717, 2005. (Trials II, III, VI, VII, IX, 11-93) (Journal impact factor 21.7).
154. Colleoni M, Li S, Gelber RD, Coates AS, Castiglione-Gertsch M, Price KN, Lindtner J, Rudenstam C-M, Crivellari D, Collins J, Pagani O, Simoncini E, Thuerlimann B, Murray E, Forbes J, Erzen D, Holmberg SB, Veronesi A, Goldhirsch A, for the International Breast Cancer Study Group. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. *Ann Oncol* 16:716-725, 2005. (Trials VII and IX) (Journal impact factor 4.3).
153. Dellapasqua S, Castiglione-Gertsch M. The choice of systemic adjuvant therapy in receptor-positive early breast cancer. *Eur J Cancer* 41:357-364, 2005. (Commentary) (Journal impact factor 3.3).
152. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. *J Clin Oncol* 23:1736-1750, 2005. (Commentary) (Journal impact factor 9.8).
151. Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam C-M, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thuerlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the International Breast Cancer Study Group experience. *J Clin Oncol* 23:1390-1400, 2005. (Trials I-VII, IX) (Journal impact factor 9.8).

2004

150. Rabaglio M, Egli G, Castiglione M. Oedeme nach Tumorbehandlung (Edema after cancer treatment). *Ther Umsch* 61:649-54, 2004.
149. Bernhard J, Zahrieh D, Coates AS, Gelber RD, Castiglione-Gertsch M, Murray E, Forbes JF, Perey L, Collins J, Snyder R, Rudenstam C-M, Crivellari D, Veronesi A, Fey MF, Price KN, Goldhirsch A, Hürny C for the IBCSG. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. *Br J Cancer* 91:1893-1901, 2004. (Trial IX)
148. International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. *Ann Oncol* 15:1749-1759, 2004. (Trials 12-93 and 14-93)
147. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. *Biostatistics* 5(3):465-81, 2004. (Trial IX)
146. Sabbioni MEE, Bernhard J, Siegrist H-P, Schmitz S-FH, Castiglione-Gertsch M, Thuerlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hürny C for the SAKK. Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? *Breast Cancer Research and Treatment* 87: 75-86, 2004. (VI, VII, VIII, IX, 13-93, 14-93)
145. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam C-M, Holmberg SB, Lindtner J, Erzen D, Collins J, Snyder R, Thuerlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A, on behalf of the IBCSG. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. *Ann Oncol* 15: 875-884, 2004. (Trials I-VII)
144. Biganzoli L, Goldhirsch A, Strahle C, Castiglione-Gertsch M, Therasse P, Aapro M, Minisini M, Piccart MJ, on behalf of BIG. Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG). *Ann Oncol* 15: 207-210, 2004.

143. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning P, Cocconi G, Stewart A, Stuart N, Snowdon C, Carpentieri M, Massimini G, Bliss JM, for the Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. *N Engl J Med* 350:1081-1092, 2004. (Trial 16-98)

142. Holmberg L, Anderson H, for the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. *Lancet* 363:453-455, 2004. (Trial 17-98)

2003

141. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. *J Natl Cancer Inst* 95:1833-46, 2003. (Trial VIII)

140. Crivellari D, Price K, Gelber RD, Castiglione-Gertsch M, Rudenstam CM, Lindtner J, Fey MF, Senn HJ, Coates AS, Collins J, Goldhirsch A for the IBCSG. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. *J Clin Oncol* 21:4517-23, 2003.

139. Gelber RD, Bonetti M, Castiglione-Gertsch M, Coates AS, Goldhirsch A for the IBCSG. Tailoring adjuvant treatments for the individual breast cancer patient. *The Breast* 12:558-68, 2003. (Trials VII and IX)

138. Aebi S and Castiglione-Gertsch M. Adjuvant endocrine therapy for the very young patients. *The Breast* 12:509-15, 2003. (Trial VIII)

137. Senn H-J, Thuerlimann B, Goldhirsch A, Wood WC, Gelber RD, Coates AS. Comments on the St. Gallen Consensus 2003 on the primary therapy of early breast cancer. *The Breast* 12:569-82, 2003.

136. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. Randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med* 349:1793-1802, 2003. (Trial 19-01)

135. Goldhirsch A, Wood W, Gelber RD, Coates AS, Thuerlimann B, Senn H-J. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. *J Clin Oncol*, 21:3357-65, 2003.

134. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thuerlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, and Collins J for the IBCSG. Risk factors for locoregional recurrence among breast cancer patients: Results from International Breast Cancer Study Group Trials I Through VII. *J Clin Oncol* 21:1205-1213, 2003. (Trials I-VII)

133. Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: Results from International Breast Cancer Study Group Trial V. *Cancer* 97:1591-1600, 2003. (Trial V)

132. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. *J Natl Cancer Inst* 95:190-197, 2003.

131. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA. Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors - A surrogate marker? *Cancer* 97:1321-1331, 2003. (Trial V)

2002

130. Colleoni M, Litman HJ, Castiglione-Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, Coates AS, Schumacher M, Bastert G, Rudenstam CM, Schmoor C, Lindtner J, Collins J, Thuerlimann B, Holmberg S, Crivellari D, Beyerle C, Neumann RLA, Goldhirsch A for the International Breast Cancer Study Group and the German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomised trials investigating 3 versus 6 courses of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil). *Br J Cancer* 86:1705-1714, 2002. (Trial VI)

129. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node negative breast cancer: A randomized trial. *J Natl Cancer Inst* 94:1054-1065, 2002. (Trial IX)

128. Castiglione-Gertsch M for the International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial of the International Breast Cancer Study Group. *American Journal of Oncology Review*. 1:286-289, 2002. (Trial IX)
127. Coates AS, Goldhirsch A, Gelber RD for the International Breast Cancer Study Group. Overhauling the breast cancer overview: are subsets subversive? *Lancet Oncology*, 2002, 3: 525 – 526.

2001

126. Kitchen PRB, Smith HJ, Henderson MA, Goldhirsch A, Castiglione-Gertsch M, Coates AS, Gusterson B, Brown RW, Gelber RD, Collins JP. Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy. *ANZ J Surg* 71:27-31, 2001. (Trials I-14)
125. Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini G, Lindtner J, Edelmann DZ, Gudgeon A, Harvey V, Gelber RD, for the International Breast Cancer Study Group (IBCSG). Effect of pregnancy on overall survival following the diagnosis of early stage breast cancer. *J Clin Oncol*, 19:1671-1675, 2001. (Trials V and VI)
124. Bernhard J, Sullivan M, Hürny C, Coates AS, Rudenstam C-M. Clinical relevance of single item quality of life indicators in cancer clinical trials. *Br J Cancer* 84:1156 – 1165, 2001. (Trials VI-VII)
123. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. *The Lancet* 358:277-286, 2001. (Trial III)
122. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderbergh J, Anbazhagan R, Styles K, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ, for the International Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. *J Clin Oncol/Classic Papers and Current Comments* 5:908-916, 2001. (Trial V)
121. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J. Meeting highlights: International consensus panel on the treatment of primary breast cancer. *J Clin Oncol* 19:3817-3827, 2001.
120. International Breast Cancer Study Group. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. *The Breast* 10 (Suppl 3): 130-138, 2001. (Trial 11-93)
119. Goldhirsch A, Gelber RD, Yothers G, Gray, RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. *J Natl Cancer Inst Monogr*, No. 30:44-51, 2001. (Trials I-VI)
118. Colleoni M, Gelber S, Coates A, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thuerlimann B, Holmberg S, Cortés-Funes H, Simoncini E, Murray E, Fey M, Goldhirsch A, for the IBCSG. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. *J Clin Oncol* 19: 4141-4149, 2001. (Trial V)

2000

117. Kiebert G, Wait S, Bernhard J, Bezjak A, Cella D, Day R, Houghton J, Moinpour C, Scott C, Stephens R. Practice and policy of measuring quality of life and health economics in cancer clinical trials: A survey among co-operative trial groups. *Quality of Life Research* 9: 1073-1080, 2000.
116. Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam C-M, Thuerlimann B, Price KN, Coates AS, Hürny C, Bernhard J, Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortés-Funes H, Veronesi A, Fey M, Goldhirsch A for the IBCSG. Burdens and benefits of adjuvant CMF and tamoxifen for elderly patients with breast cancer: The IBCSG Trial VII. *J Clin Oncol* 18: 1412-1422, 2000. (Trial VII)
115. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam C, Lindtner J, Collins J, Thuerlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A, for the International Breast Cancer Study Group. Early start of adjuvant chemotherapy improves treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptor. *J Clin Oncol* 18: 584-590, 2000. (Trials I-V)
114. Castiglione-Gertsch M, Gelber RD, Coates AS, O'Neill A, Goldhirsch A, for the IBCSG. Systemic adjuvant treatment for premenopausal node-negative breast cancer. *Eur J Canc*, 36: 549-550, 2000. (Trial VIII)
113. Murray S, Cole B. Variance and sample size calculations in quality-of-life-adjusted survival analysis (Q-TWiST). *Biometrics*, 56: 173-182, 2000.
112. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thuerlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortés-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A, for the International Breast Cancer Study

Group (IBCSG). Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? *Lancet*, 355: 1869-1874, 2000. (Trials I-VI)

111. Sabbioni MEE, Siegrist HP, Bacchi M, Bernhard J, Castiglione M, Thuerlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hüry C. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. *Breast Cancer Research and Treatment*, 59: 279-287, 2000.

110. Goldhirsch A, Francis P, Castiglione-Gertsch M, Gelber RD, Coates AS. The taxanes as adjuvant for breast cancer: “an update”, “too early”, or “don’t confuse me with data”? *Lancet*, 356: 507, 2000.

109. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. *Stat in Med*, 19: 2595-2609, 2000. (Trial VII)

108. Colleoni M, O’Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thuerlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortés-Funes H, Veronesi A, Fey M, Rudenstam C-M, for the International (Ludwig) Breast Cancer Study Group. Identifying breast cancer patients at high risk for bone metastases. *J Clin Oncol*, 18: 3925-3935, 2000. (Trials I-VII)

107. Coates AS, Hüry C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, for the IBCSG. Quality of life scores predict outcome in metastatic but not in early breast cancer. *J Clin Oncol*, 18: 3768-3774, 2000. (Trials VI-VII)

1999

106. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Gusterson B, Neville AM. The role of the immunohistochemical detection of lymph node metastases in the management of breast cancer. *Lancet* 354:896-900, 1999. (Trial V)

105. Colleoni M, Price K, Castiglione-Gertsch M, Gelber R, Coates A, Goldhirsch A, for the International Breast Cancer Study Group (IBCSG). Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, fluorouracil (CMF regimen). *Lancet* 354:130-131, 1999. (Trials I-VII)

104. Bonetti M, Cole BF, Gelber RD. A method-of-moments estimation procedure for categorical quality-of-life data with nonignorable missingness. *JASA* 94: 1025-1034, 1999. (Trial VII)

1998

103. Pinder, SE, Murray, S, Ellis, IO, Trihia, H, Elston, CW, Gelber, RD, Goldhirsch, A, Lindtner, J, Cortés-Funes, H, Simoncini, E, Byrne, MJ, Golouh, R, Rudenstam, CM, Castiglione-Gertsch, M, Gusterson, BA. The importance of histological grade in invasive breast carcinoma and response to chemotherapy. *Cancer* 83:1529-1539, 1998. (Trial V)

102. Pagani O, O’Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam C.-M, Lindtner J, Collins J, Crivellari D, Coates A, Cavalli F, Thuerlimann B, Simoncini E, Fey M, Price K, Senn H.J. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. *Eur J Cancer* 34:632-640, 1998. (Trial VI)

101. Colleoni M, Price K, Goldhirsch A, Castiglione-Gertsch M, Coates A, Lindtner J, Collins J, Gelber RD, Thuerlimann B, Rudenstam CM, for the IBCSG. Dose-response effect of adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in node-positive breast cancer. *Eur J Cancer* 34:1693-1700, 1998. (Trials I-V)

100. Bernhard J, Hüry Ch, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Galligioni E, Marini G, Thuerlimann B, Forbes JF, Goldhirsch A, Senn H-J, Rudenstam C-M, for the IBCSG. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. *Br J Cancer* 78:686-693, 1998. (Trials VI-VII)

99. Gelber RD, Bonetti M, Cole BF, Gelber S, Goldhirsch A. Quality of life assessment in the adjuvant setting: Is it relevant? In *Adjuvant therapy of primary breast cancer VI*. Senn H-J, Gelber RD, Goldhirsch B, Thuerlimann B (Eds.), Recent results in cancer research, Springer-Verlag, Berlin, 1998, pp 373-389.

98. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: an overview of the randomised trials. *Lancet* 352:930-942, 1998. (Trial III)

97. Coates AS, Gelber RD, Goldhirsch A, for the IBCSG. Subsets within the chemotherapy overview. *Lancet* 352:1783-1784, 1998.

96. Bernhard J, Peterson HF, Coates AS, Gusset H, Isley M, Hinkle R, Gelber RD, Castiglione-Gertsch M, Hüry C for the International Breast Cancer Study Group. Quality of life assessment in international breast cancer study group (IBCSG) trials: practical issues and factors associated with missing data. *Stat Med* 17:587-601, 1998. (Trials VI-VII)

95. Goldhirsch A, Colleoni M, Coates AS, Castiglione-Gertsch M, Gelber RD, for the International Breast Cancer Study Group. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? *Ann Oncol* 9:489-493, 1998.
94. Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M, Gelber RD for the International Breast Cancer Study Group. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. *J Clin Oncol* 16(4):1358-1362, 1998.
93. Goldhirsch A, Glick JH, Gelber RD, Senn H-J. (Commentary) Meeting Highlights: International consensus panel on the treatment of primary breast cancer. *J Natl Cancer Inst* 90(2):1601-1608, 1998.
92. Goldhirsch A, Coates AS, Castiglione-Gertsch M, Gelber RD. (Commentary) New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction? *Ann Oncol* 9:973-976, 1998.

1997

91. The International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. *J Clin Oncol* 15:1385-1393, 1997. (Trial VII)
90. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam C-M, Castiglione-Gertsch M, Allegra CJ, Johnston PG. The prognostic importance of Thymidylate Synthase expression in early breast cancer. *J Clin Oncol* 15:1923-1931, 1997. (Trial V)
89. Castiglione-Gertsch M, Tattersall M, Hacking A, Goldhirsch A, Gudgeon A, Gelber RD, Lindtner J, Coates A, Collins J, Isley M, Senn H-J, Rudenstam C-M for the IBCSG. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. *Eur J Cancer* 33:2321-2325, 1997. (Trials I-V)
88. Goldhirsch A, Gelber R, Castiglione M, O'Neill A, Thuerlimann B, Rudenstam C-M, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Simoncini E, Fey M, Pagani O, Price K, Senn H-J and other members of the IBCSG. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. *Ann Oncol* 8:751-756, 1997. (Trial VI)
87. Bernhard J, Hüry C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn H-J, Rudenstam C-M for the International Breast Cancer Study Group (IBCSG). Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. *Ann Oncol* 8:825-835, 1997. (Trials VI-VII)

1996

86. Gusterson BA, Gelber RD, Goldhirsch A., Price KN, Säve-Söderbergh J, Anbazhagan R, Styles K, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ for the International Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. *Classic Papers and Current Comments* 1:32-40, 1996. (Trial V)
85. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS, for the Ludwig Breast Cancer Study Group. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. *Classic Papers and Current Comments* 1:152-160, 1996. (Trial III)
84. Hüry C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Rudenstam C-M, Lindtner J, Collins J, Crivellari D, Simoncini E, Forbes JF, Senn H-J, Goldhirsch A for the International Breast Cancer Study Group (IBCSG): Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. *Lancet* 347:1279-1284, 1996. (Trials VI-VII)
83. The International Breast Cancer Study Group: Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. *J Clin Oncol* 14:1885-1894, 1996. (Trial VI)
82. Bernhard J, Hüry C, Coates A, Gelber R: Applying Quality of Life Principles in International Cancer Clinical Trials. *Int Clin Trials* 72:693-705, 1996. (Trials VI-VII)
81. Marini G, Murray S, Goldhirsch A, Gelber R, Castiglione M, Price K, Tattersall M, Rudenstam CM, Collins J, Lindtner J, Cavalli F, Cortés-Funes H, Gudgeon A, Forbes J, Galligioni E, Coates A, Senn HJ: The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. *Ann Oncol* 7:245-250, 1996. (Trial I)
80. Wallgren A, Bernier J, Gelber RD, Goldhirsch A, Roncadin M, Joseph D, Castiglione-Gertsch M for the International Breast Cancer Study Group: Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. *Int J Rad Onc Biol Phys* 35:649-659, 1996. (Trials VI-VII)

79. Hürny C, Bernhard J, Coates A, Peterson HF, Castiglione M, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Goldhirsch A, Senn HJ, for the International Breast Cancer Study Group (IBCSG). Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. *Med Care* 34:234-248, 1996. (Trials VI-VII)
78. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson N-O, Sevela P. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: a meta-analysis of quality-adjusted survival. *Lancet* 347:1066-1071, 1996.
77. Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. *J Natl Cancer Inst* 88:1039-1045, 1996.
76. Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer. *Semin Oncol* 23:494-505, 1996.

1995

75. Goldhirsch A, Gelber RD, Castiglione M, Price K, Rudenstam CM, Lindtner J, Collins J, Senn HJ, Cavalli F, Galligioni E, Fey M, Gudgeon A, Cortés-Funes H, Tattersall M, Marini G, Byrne M, Snyder R, Forbes JF, Kay R, Hürny C, Thuerlimann B, Reed R, Gusterson B, Torhorst J, Säve-Söderbergh J, Coates A for the International Breast Cancer Study Group. The best available adjuvant treatments are within the framework of clinical trials. *Isr J Med Sci* 31:145-154, 1995. (Trials I-V)
74. Crivellari D, Price KN, Hagen M, Goldhirsch A, Gelber RD, Castiglione M, Coates AS, Rudenstam CM, Collins J, Lindtner J, Cortés-Funes H, Gudgeon A, Simoncini E, Byrne M, Schnürch HG, Fey M, Tattersall MHN, Forbes JF, Cavalli F, Reed R, Senn H-J for the International (Ludwig) Breast Cancer Study Group (IBCSG): Routine tests during follow-up of patients after primary treatment for operable breast cancer. *Ann Oncol* 6:769-776, 1995. (Trials I-V)
73. Goldhirsch A, Wood W, Senn HJ, Glick J, Gelber R. Meeting highlights: International consensus panel on the treatment of primary breast cancer. *J Natl Cancer Inst* 87:1441-1445, 1995.
72. Cole BF, Gelber RD, Goldhirsch A. A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. *Stat Med* 14:1771-1784, 1995.
71. Gelber RD, Cole BF, Gelber S, Goldhirsch A. Comparing treatments using quality-adjusted survival: The Q-TWiST method. *Amer Stat* 49:161-169, 1995.
70. Gelber RD, Cole BF, Goldhirsch A, Bonadonna G, Howell A, McArdle CS, Mouridsen HT, Rubens RD, Welvaart K. Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. *Cancer J Sci Amer* 1:114-121, 1995.

1994

69. Cole BF, Gelber RD, Anderson KM, for the International Breast Cancer Study Group: Parametric approaches to quality adjusted survival analysis. *Biometrics* 50:621-631, 1994.
68. Hürny C, Bernhard J, Coates A, Castiglione M, Peterson H, Gelber RD, Rudenstam C-M, Goldhirsch A, Senn H-J for the International Breast Cancer Study Group: Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient estimation. *Ann Oncol* 5:65-74, 1994. (Trials VI-VII)
67. Goldhirsch A, Gelber R, Price K, Castiglione M, Coates A, Rudenstam C-M, Collins J, Lindtner J, Hacking A, Marini G, Byrne M, Schnürch G, Brunner K, Tattersall MHN, Forbes J, Senn H-J for the International Breast Cancer Study Group: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. *Lancet* 343:377-381, 1994. (Trials I-V)
66. Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam CM, Lindtner J, Collins J, Senn HJ, Brunner KW, Galligioni E, Cavalli F, Gudgeon A, Cortes-Funes H, Tattersall M, Marini G, Byrne M, Snyder R, Forbes JF, Hürny C, Coates A for the International Breast Cancer Study Group: Present and future projects of the International Breast Cancer Study Group. *Cancer (Suppl.)* 3:1139-1149, 1994.
65. Goldhirsch A, Gelber RD, Castiglione M: Testing tumor dormancy in breast cancer. *J Natl Cancer Inst* 7:558, 1994.
64. Hürny C, Bernhard J: Lessons Learned from Measuring Health-Related Quality of Life in Oncology. *J Clin Oncol* 12:1994, 1994.

63. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Hacking A, Cortes-Funes, Forbes J, Simpson J, Tattersall MHN, Brunner K, Cavalli F, Senn HJ for the International Breast Cancer Study Group. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. *Ann Oncol* 5:717-724, 1994. (Trials I-IV)

62. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, Ebbs S, Micklem K, Price K, Gelber R, Reed R, Senn H-J, Goldhirsch A, Dyer MJS. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. *Ann Oncol* 5:409-414, 1994. (Trials I-IV)

1993

61. Hürny C, Bernhard J, Bacchi M, van Wegberg B, Tomamichel M, Spek U, Coates A, Castiglione M, Goldhirsch A, Senn J-H for the SAKK and IBCSG: The perceived adjustment to chronic illness scale (PACIS): a global indicator of coping of operable breast cancer patients for clinical trials. *Support Care Cancer* 1:200-208, 1993.

60. Gelber RD, Goldhirsch A, Coates AS, for the International Breast Cancer Study Group: Adjuvant therapy for breast cancer: understanding the overview. *J Clin Oncol* 11:580-585, 1993.

59. Gelber RD, Goldhirsch A, Cole BF, for the International Breast Cancer Study Group: Evaluation of effectiveness: Q-TWiST. *Cancer Treat Rev* 19:73-84, 1993.

58. Cole BF, Gelber RD, Goldhirsch A: Cox regression models for quality adjusted survival analysis. *Stat Med* 12:975-987, 1993.

57. Goldhirsch A, Gelber RD, Castiglione M, Senn HJ: Doxorubicin adjuvant combinations for breast cancer - IBCSG's reply. *Lancet* 342:1551, 1993.

56. Gelber RD, Goldhirsch A, Cole BF; for the IBCSG: Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. *Cont Clin Trials* 14:485-499, 1993.

55. Gusterson BA, Taylor CW, Price KN, Gelber RD, Säve-Söderbergh J, Anbazhagan R, et al. Prognostic value of Helix Pomatia in breast cancer. *Br J Cancer* 68:146-150, 1993. (Trial V)

1992

54. Neville AM, Bettelheim R, Gelber R, Säve-Söderbergh J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN, Isley M, Rudenstam CM, Collins J, Castiglione M, Senn HJ, Goldhirsch A for the International Breast Cancer Study Group: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. *J Clin Oncol* 10:696-705, 1992. (Trial V)

53. Hürny Ch, Bernhard J, Gelber RD, Coates A, Castiglione M, Isley M, Dreher D, Peterson H, Goldhirsch A, Senn JH for the International Breast Cancer Study Group: Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. *Eur J Cancer* 28:118-124, 1992. (Trials VI-VII)

52. Goldhirsch A, Castiglione M, Gelber RD for the International Breast Cancer Study Group: A single perioperative adjuvant chemotherapy course for node-negative breast cancer: five-year results of trial V. *J Natl Cancer Inst Monogr* 11:89-96, 1992. (Trial V)

51. Gelber RD, Goldhirsch A for the International Breast Cancer Study Group: Reporting and interpreting adjuvant therapy clinical trials. *J Natl Cancer Inst Monogr* 11:59-69, 1992.

50. Gelber RD, Goldhirsch A, Hürny Ch, Bernhard J, Simes RJ for the International Breast Cancer Study Group: Quality of life in clinical trials of adjuvant therapies. *J Natl Cancer Inst Mongr* 11:127-135, 1992.

49. Spataro V, Price K, Goldhirsch A, Cavalli F, Simoncini E, Castiglione M, Rudenstam C-M, Collins J, Lindtner K, Gelber RD for the International Breast Cancer Study Group (formerly Ludwig Group): Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. *Ann Oncol* 3:733-740, 1992. (Trials I-V)

48. Gusterson BA, Gelber RD, Goldhirsch A., Price KN, Säve-Söderbergh J, Anbazhagan R, Styles K, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ for the International Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. *J Clin Oncol* 10:1049-1056, 1992. (Trial V)

47. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. *Lancet* 339:1-15, 71-85, 1992.

46. Gelber RD, Coates AS, Goldhirsch A: Adjuvant therapy for breast cancer: the overview (editorial). *B Med J* 304:859-860, 1992.

45. Glick JH, Gelber RD, Goldhirsch A, Senn HJ: Meeting highlights: adjuvant therapy of primary breast cancer. *J Natl Cancer Inst* 84:1479-1485, 1992.
44. Gelber RD, Coates AS, Goldhirsch A: Meta-analysis: the fashion of summing up evidence. Part II: Interpretation and uses. *Ann Oncol* 3:683-691, 1992.
43. Goldhirsch A: Trattamento precauzionale del carcinoma mammario: Consensus 1992. *Tribuna Med Ticinese* 57:767-770, 1992.
42. Crivellari D, Cannizzaro R, Galligioni E, Valentini M, Monfarini S, Castiglione M: Adjuvant therapy for primary breast cancer in a female patient affected by autoimmune liver disease: Does it cure breast cancer and primary biliary cirrhosis? *Tumori* 78:395-396, 1992.
41. Glick JH, Gelber RD, Goldhirsch A, Senn HJ. Adjuvant therapy of primary breast cancer. *Ann Oncol* 3:801-807, 1992.

1991

40. Castiglione M, Goldhirsch A: Is the adjuvant therapy for node-negative breast cancer necessary? *Diagn Oncol* 1:98-101, 1991.
39. Goldhirsch A, Gelber RD, Castiglione M, for the International Breast Cancer Study Group: Adjuvant therapy of breast cancer. *Eur J Cancer* 27:389-399, 1991.
38. Gelber RD, Goldhirsch A, Cavalli F: Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer. *Ann Int Med* 114:621-628, 1991. (Trial V)
37. Butow P, Coates A, Dunn S, Bernhard J, Hürny C: On the receiving end IV: Validation of quality of life indicators. *Ann Oncol* 2:597-603, 1991.
36. Castiglione M, Goldhirsch A: Die adjuvant systemische Therapie beim Mammakarzinom heute. *Acta Chirurgica Austriaca* 2:49-56, 1991.
35. Anbazhagan R, Gelber RD, Bettelheim R, Goldhirsch A, Gusterson BA. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. *Ann Oncol* 2:47-53, 1991. (Trials I-IV)
34. Gelber R, Goldhirsch A. Meta-analysis. The fashion of summing-up the evidence. Part I. Rationale and conduct. *Ann Oncol* 2:461-468, 1991.

1990

33. Goldhirsch A, Gelber RD, Castiglione M, for the International Breast Cancer Study Group: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. *Ann Oncol* 1:183-188, 1990.
32. International (Ludwig) Breast Cancer Study Group: Prognostic importance of occult axillary lymph node metastases from breast cancers. *Lancet* 335:1565-1568, 1990. (Trial V)
31. International Breast Cancer Study Group: Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. *Ann Oncol* 1:30-35, 1990. (Trial II)
30. Castiglione M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. *J Clin Oncol* 8:519-526, 1990. (Trial IV)
29. Coates A, Forbes J, for the Australian-New Zealand Breast Cancer Trials Group: Clinical trials in breast cancer in Australia and New Zealand. *Med J Aust* 152:601-606, 1990.
28. Forbes JF: Surgery, Kinetics and biological considerations in planning adjuvant therapy protocols. Effects of therapy on biology and kinetics of the residual tumor, Part A: Preclinical aspects 133-146, 1990.
27. Richner J, Gerber HA, Locher GW, Goldhirsch A, Gelber RD, Gullick WJ, Berger MS, Groner B, Hynes NE. c-erbB-2 protein expression in node negative breast cancer. *Ann Oncol* 1:263-268, 1990.
26. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. *Stat Med* 9:1259-1276, 1990.

1989

25. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS, for the Ludwig Breast Cancer Study Group. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. *J Clin Oncol* 7:36-44, 1989.
24. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. *N Engl J Med* 320:491-496, 1989. (Trial V)

23. Gelber RD, Gelman RS, Goldhirsch A: A quality of life oriented endpoint for treatment comparisons. *Biometrics* 45:781-795, 1989.
22. Gelber RD, Goldhirsch A: Comparison of adjuvant therapies using quality-of-life considerations. *Int J of Tech Ass in Health Care* 5:401-413, 1989.
21. Gelber RD, Goldhirsch A. Clinical trials for clinicians. *Chest* 96 (suppl): 97S-101S, 1989.

1988

20. Goldhirsch A, Gelber RD, Castiglione M, for the Ludwig Breast Cancer Study Group: Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognoses. *J Clin Oncol* 6:89-97, 1988. (Trials I-II)
19. Ludwig Breast Cancer Study Group. On the safety of perioperative adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in breast cancer. *Eur J Cancer Clin Oncol* 24:1305-1308, 1988. (Trial V)
18. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. *N Engl J Med* 319:677-683, 1988. (Trial V)
17. Early Breast Cancer Trialists' Collaborative Group (Henderson IC, Mouridsen H (co-chairmen), Gelber RD, Goldhirsch A, Forbes J for the Ludwig Breast Cancer Study Group, et al.) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. *N Engl J Med* 319:1681-1692, 1988.
16. Goldhirsch A, Gelber RD, Castiglione M: Chemohormonal therapy of operable breast cancer. *Cancer Investigation* 6:558-560, 1988.

1987

15. Hedley DW, Rugg CA, Gelber RD, for the Ludwig Breast Cancer Study Group: Association of DNA index and S-phase fraction with prognosis of N+ early breast cancer. *Cancer Res* 47:4729-4735, 1987. (Trials I-IV)

1986

14. Pedrazzini A, Gelber RD, Isley M, Castiglione M and Goldhirsch A, for the Ludwig Breast Cancer Study Group: First repeated bone scan in the observation of patients with operable breast cancer. *J Clin Oncol* 4:389-394, 1986. (Trials I-IV)
13. Goldhirsch A and Gelber RD, for the Ludwig Breast Cancer Study Group: Adjuvant treatment for early breast cancer: the Ludwig Breast Cancer Studies. *J Natl Cancer Inst Monogr* 1:55-70, 1986. (Trials I-IV)
12. Gelber RD and Goldhirsch A, for the Ludwig Breast Cancer Study Group: A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. *J Clin Oncol* 4:1772-1779, 1986. (Trial III)
11. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, Golouh R, Save-Soderbergh J, Holloway L, Russell I, Rudenstam C-M, for the Ludwig Breast Cancer Study Group: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. *Cancer* 58:2662-2670, 1986. (Trials I-IV)

1985

10. Rudenstam C-M, for the Ludwig Breast Cancer Study Group: The Ludwig breast cancer studies in postmenopausal patients with axillary node metastasis. *Rev. Endocrine-related Cancer* 17:25-32, 1985. (Trials III-IV)
9. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Holloway L, Russel I and Rudenstam C-M: Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. *Hum Pathol* 16:1212-1218, 1985. (Trials I-IV)
8. Goldhirsch A, for the Ludwig Breast Cancer Study Group: Adjuvant treatment in operable breast cancer. *J Steroid Biochem* 23:1155-1160, 1985. (Trials I-IV)
7. Ludwig Breast Cancer Study Group: A randomized Trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. *Cancer Res* 45:4454-4459, 1985. (Trial I)
6. Ludwig Breast Cancer Study Group: Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. *J Clin Oncol* 3:1059-1067, 1985. (Trial II)

1984

5. Ludwig Breast Cancer Study Group: Randomised trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. *Lancet* i:1256-1260, 1984. (Trials III and IV)
4. Davis B, Zava DT, Locher G, Goldhirsch A, Hartman WH: Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. *Eur J Cancer Clin Oncol* 20:375-382, 1984.

1983

3. Ludwig Breast Cancer Study Group: Toxic effects of early adjuvant chemotherapy for breast cancer. *Lancet* ii:542-544, 1983.
2. Jordan VC, Zava DT, Eppenberger U, Kiser A, Sebeck S, Dowdle E, Krozowski Z, Bennett RC, Funder J, Holdaway IM, Wittliff JL. Reliability of steroid hormone receptor assays: an international study. *Eur J Cancer Clin Oncol* 19:357-363, 1983.

1982

1. Zava DT, Wyler-Von Ballmoos A, Goldhirsch A, Roos W, Takahashi A, Eppenberger U, Arrenbrecht S, Martz G, Losa G, Gomez F and Guelpa C: A quality control study to assess the inter-laboratory variability of routine estrogen and progesterone receptor assays. *Eur J Cancer Clin Oncol* 18:713-721, 1982.